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ABSTRACT OF DISSERTATION

THE UNDERLYING MECHANISM(S) OF FASTING INDUCED
NEUROPROTECTION AFTER MODERATE TRAUMATIC BRAIN INJURY.
Traumatic brain injury (TBI) is becoming a national epidemic, as it accounts for
1.5 million cases each year. This disorder affects primarily the young population and
elderly. Currently, there is no treatment for TBI, which means that ~2% of the U.S.
population is currently living with prolonged neurological damage and dysfunction.
Recently, there have been many studies showing that TBI negatively impacts
mitochondrial function. It has been proposed that in order to save the cell from
destruction mitochondrial function must be preserved. The ketogenic diet, originally
designed to mimic fasting physiology, is effective in treating epilepsy. Therefore, we
have used fasting as a post injury treatment and attempted to elucidate its underlying
mechanism. 24 hours of fasting after a moderate TBI increased tissue sparing, cognitive
recovery, improved mitochondrial function, and decreased mitochondrial biomarkers of
injury. Fasting results in hypoglycemia, the production of ketones, and the upregulation
of free fatty acids (FFA). As such, we investigated the neuroprotective effect of
hypoglycemia in the absence of fasting through insulin administration. Insulin
administration was not neuroprotective and increased mortality in some treatment groups.
However, ketone administration resulted in increased tissue sparing. Also, reduced
reactive oxygen species (ROS) production, increased the efficiency of NADH utilization,
and increased respiratory function. FFAs and uncoupling proteins (UCP) have been
implicated in an endogenously regulated anti-ROS mechanism. FFAs of various chain
lengths and saturation were screened for their ability to activate UCP mediated
mitochondrial respiration and attenuate ROS production. We also measured FFA levels in
serum, brain, and CSF after a 24 hour fast. We also used UCP2 transgenic overexpressing
and knockout mice in our CCI injury model, which showed UCP2 overexpression
increased tissue sparing, however UCP2 deficient mice did not show a decrease in tissue
sparing, compared with their wild type littermates. Together our results indicate that post
injury initiated fasting is neuroprotective and that this treatment is able to preserve
mitochondrial function. Our work also indicates ketones and UCPs may be working
together to preserve mitochondrial and cellular function in a concerted mechanism, and
that this cooperative system is the underlying mechanism of fasting induced
neuroprotection.
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Chapter 1

Traumatic Brain Injury, Mitochondria, and Fasting
Traumatic Brain Injury
With over 1.5 million injuries every year, Traumatic brain injury (TBI) has
become a widespread phenomenon in our country. As this disorder can present without
any outward sign of physical damage and because the effects often render the patient
unable to communicate effectively, it has become a largely „silent epidemic‟ (Jennett
1998; Thurman et al. 1999; Jager et al. 2000; CDC 2003; Langlois et al. 2006). Although
advancements in medicine over the past century have increased the survival rates of TBI
patients, there is unfortunately a growing population of individuals who sustain a mild to
moderate TBI who do not seek immediate medical treatment (~25%), and often develop
prolonged and chronic neurological symptoms (CDC 2003). The growing population of
injured patients has presented our society with an enormous economic and social burden,
as these patients are frequently unable to properly reintegrate in to their previous
professional and social networks. They become exceedingly dependent on family and
social outreach programs to maintain daily quality of life; which can cause their health
care to cost the nation tens of billions dollars per year (Thurman et al. 1999; Langlois et
al. 2006). While there are treatment options designed to allow the person to survive their
injuries, consisting of minimizing acute brain edema, decreasing intracranial pressure,
and the prevention of peripheral complications, there is no current treatment to attenuate
or recover the loss of neural tissue (Hatton 2001).
Perhaps the most insidious aspect of TBI is that it can occur without obvious signs
of injury to the patient‟s body. There have been recorded medical incidences of
1

mysterious neurological disorders dating back to World War I. Physicians in the British
armed forces had then given it the somewhat enigmatic label of “shell shock” (SS) (Jones
et al. 2007). Although some cases could be attributed to psychosis, by 1917 SS was
responsible for 14% of all discharges from the armed forces, and accounted for 33% of
all discharges of non-wounded soldiers (Jones et al. 2007). It had become so prevalent
throughout the armed forces and had such a wide array of presenting symptoms that it
was highly debated whether or not it was a real condition, and the etiology and
management was highly disputed for much of the early 20th century. By the end of WWI
the prevalence of SS began to incur a large financial burden upon the British armed
forces, primarily due to the 32,000 pensions that had been awarded to “neurasthenic”
soldiers suffering from SS with no obvious cerebral injury (Jones et al. 2007). The
controversial definition of the disorder and its method of treatment, in addition to the
development of public controversy and stigma over diagnosis, delayed the development
of a treatment protocol and even caused the British army to ban the use of the term “shell
shock” from medical reports (Jones et al. 2007).
During WWII the British army banned the SS terminology in hopes of avoiding
another epidemic of these cases, which they may or may not have viewed as physical
disorders. However, with the start of the war it became readily apparent that disavowing
the existence of this disorder did not prevent another epidemic. In response to the army
regulations regarding this disorder, alternative terminology arose in its place, such as
postconcussional syndrome (PS) or posttrauma concussion state (coined by (Schaller
1939). Eventually, physicians began to realize that many of the soldiers that suffered
from this concussed state had been in close proximity to an explosion during battle. This
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led them to speculate that some force, that had no perceptible outward affect on the body,
had a substantial effect on fragile neural tissue. In an attempt to, once again, clarify the
etiology of this disorder, Denny-Brown suggested that it was the timeline of symptom
presentation within the individual patient instead of the symptom type that was the key
factor between severe head injury and PS. His etiological account indicated that severe
head injury would present with immediate neurologic symptoms that would trend toward
recovery; whereas PS would have delayed onset of neurologic symptoms with a trend
toward worsening symptoms (Jones et al. 2007). It has been estimated that 50% of
patients with a mild TBI can develop post concussive syndrome consisting of dizziness,
headaches, cognitive dysfunction, sleep disorders, and depression (Alexander 1995;
Bazarian et al. 1999; CDC 2003; Langlois et al. 2006; Rapoport et al. 2006). This delayed
development of symptoms in the mild to moderate patient populations is perhaps the
most unfortunate aspect of this condition, as soldiers and civilians can often suffer
immense psychiatric morbidity without realizing that they require medical treatment for a
physical injury (Setnik et al. 2007). A recent online polling study indicated that 42% of
their respondents who suffered a TBI failed to seek medical care, which is considerably
higher than the CDC estimate of 25%. It has been observed clinically that even mild or
moderate TBI can require neurosurgical intervention, and any delay in treatment could
prove to be costly in terms of cognitive and functional recovery (Setnik et al. 2007).
Of the more than 1.5 million military personnel deployed since 2001 to the
Middle East, approximately 25% of the injured service members have reported brain
injury (Hoge et al. 2008). Unpublished data from the department of defense indicates that
blast injuries are the leading cause of TBI in war zones; and has been labeled as a
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signature injury of the current Middle Eastern conflicts (Hoge et al. 2008). Recently the
ravages of TBI has been documented through the unfortunate injury of network news
anchor Bob Woodruff, which showed the grim reality of the recovery process of this
disorder and its effects on patients lives in terms of cognitive dysfunction and its impact
on family dynamics (Woodruff et al. 2007). Although the TBI sustained by Woodruff
was severe, mild and moderate injury have also become a long term problem coupled
with prolonged cognitive dysfunction within the armed forces population, with an
approximately 18% prevalence in various reports (Hoge et al. 2008). In addition to
prolonged cognitive deficits, this injury population also has an increased predisposition to
the development of post traumatic stress disorder (PTSD). There is also a problem of
failure to report due to a perceived stigma concerning psychological problems within the
armed forces population; which could contribute to the development of chronic
neurologic dysfunctions within this population of injured patients (Hoge et al. 2004).
Within the civilian population of the United States ~2% of the population (5.3
million) is currently living with long-term disabilities resulting from TBI (Langlois et al.
2006). The leading causes of TBI (Figure 1.1) are falls and motor vehicle accidents,
followed closely by assault and incidents in which the head is “struck by/against” an
object (Langlois et al. 2006). There has also been an increasing population of pediatric
(5-18 years) TBI cases resulting from sports related injuries, which can often be
misdiagnosed as the symptoms manifest as lethargy, irritability or fatigue (CDC 2003;
Yang et al. 2008). TBI has a biphasic age-related incidence; occurring in young (< 25)
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Figure 1.1: Traumatic brain injury causes.
The leading cause of traumatic brain injury is falls at 28%. This is closely followed by
motor vehicle accidents (20%), struck by/against events (19%), and violence (11%).
Suicide and other/unknown injury mechanisms account for the remaining 22% of
traumatic brain injuries. This figure was compiled based on data from (CDC 2003;
Langlois et al. 2006)

and elderly (>75) populations (Langlois et al. 2006; Rutland-Brown et al. 2006). Over
50,000 deaths are attributed to TBI each year, as well as 235,000 hospitalizations and
1,111,000 emergency department visits (Figure 1.2). With such a high incidence and
great propensity for the development of chronic symptoms, the total medical costs
incurred by individuals currently living with TBI within the U.S. can reach
5

Figure 1.2: Traumatic brain injury morbidity and mortality.
Of the 1.5 million annual cases of traumatic brain injury in the United States, 3% result in
fatalities, whereas 55% are treated and released from emergency departments (ED).
Hospitalization accounts for 17% of the cases seen annually, and 25% of total cases do
not seek medical treatment. This figure was compiled from data contained in (CDC 2003;
Langlois et al. 2006)

$50 billion dollars per year. This figure increases to $60 billion when lost productivity of
these individuals is factored in; however, these figures do not account for how this
disorder impacts social and family dynamics (Langlois et al. 2006; Rutland-Brown et al.
2006). As such, there is a clear need for the development of neuroprotective therapies and
effective protocols for the treatment of TBI.
6

Mitochondrial Structure, Function, and Posttraumatic Dysfunction
The development of mitochondrial function was the basis for the progression
toward multi-cellular organisms. It was at this evolutionary crossroads that the cell was
able to produce enough energy, in the form of ATP, to form highly complex
interconnected networks that developed into the organ systems we see in the human body
as well as all other organisms (Lane 2006). Underscoring the dependence on
mitochondrial ATP production is the evolutionary development of all multi-cellular
organisms upon this planet to require oxygen utilization through some sort of respiration.
It is essential that mitochondria are provided with adequate oxygen in order for the cell to
maintain homeostatic regulation of its intracellular processes (Lane 2006). The
importance of oxygen consumption is highly evident when we examine any pathological
disease in which tissues become oxygen deprived (ischemic) for even the shortest time
period. These regions undergo massive cellular loss as a result of mitochondrial damage
and dysfunction, leading to the initiation of cell death pathways, such as necrosis and
apoptosis (Obrenovitch 2008).
Although we have only been studying mitochondria since the turn of the 20th
century, these organelles have proven to be one of the most important discoveries in the
history of cellular research. Ever since Kolliker (1850), Altman (1890), and Benda (1898)
described their presence in cells we have been fascinated with their function. The first
Nobel Prize for mitochondrial research was awarded to Meyerhof in 1922 for the
discovery of the connection between substrate oxidation and oxygen consumption in
relation to glycolysis. Next to be awarded in 1931 was the work done by Warburg on the
nature and mode of action of the “respiratory enzyme”, indicating that ATP production
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was coupled with enzymatic oxidation of glyceraldehyde phosphate. Szent-Gyorgyi was
awarded the Nobel Prize in 1937 for the discovery of the connection with biological
combustion process of dicarboxylic acids within mitochondrial respiration. The most
recent Nobel was awarded in 1997 to Boyer and Walker for their discovery of the
enzymatic mechanism underlying the synthesis of ATP. Although we have learned much
over the past century about mitochondrial bioenergetics, there remains a great deal to be
discovered.
Indeed, mitochondrial function plays an integral role in all cellular function,
therefore in order to discuss mitochondrial dysfunction we must first discuss normal
mitochondrial structure and function (Figure 1.3). Mitochondria are intracellular
organelles with a dual (inner and outer) membrane system, each of which is responsible
for specific functions. The outer membrane (OM) contains many transporter proteins and
the inner membrane (IM) exhibits many folds, termed cristae, which increase the surface
area available for mitochondrial respiration (Nicholls et al. 2002). The space enclosed by
the IM is called the matrix and contains enzymes involved in cellular metabolism and
calcium regulation. Within the IM lipid bilayer there are a series of five protein
complexes that comprise the electron transport chain (ETC), which functions as the
primary source of ATP production within the cell. Complex I (NADH-Ubiquinone
Oxidoreductase), which is embedded within the IM, converts NADH to NAD+ by
accepting an electron into the Fe-S center of the protein (Nicholls et al. 2000). As a
byproduct of this electron donation, a proton is translocated from the matrix to the
intermembrane space (IMS), which is located between the inner and outer membranes.
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Figure 1.3: Overview of the electron transport chain.
The electron transport chain (ETC) is made up of 5 inner membrane proteins within the
mitochondria. The first protein in this chain is complex I, which accepts electrons from
NADH, facilitating proton (H+) translocation into the intermembrane space from the
mitochondrial matrix. Complex II, which is only attached to the inner side of the inner
membrane, accepts electrons from FADH2, however does not translocate protons (H+).
Complex II is also a component of the Krebs cycle, which is responsible for the
production of ETC substrate production. The electrons from complex I & II are
transported to complex III via ubiquinone (Co enzyme Q10), which also causes a
translocation of protons (H+) into the intermembrane space. The Q-cycle of complex III
transfers the electrons to Cytochrome c, which then transfers them to complex IV,
resulting in another proton (H+) translocation. Complex IV is responsible for the
production of water by using oxygen as the final electron acceptor. Complex V
(ATPsynthase) uses the proton (H+) gradient (ΔΨ) created by complex I-IV to catalyze
the phosphorylation of ADP to create energy in the form of ATP. Superoxide (O2-.) is
produced by the escape of electrons from complex I or III. Normally it is converted by
Manganese Superoxide Dismutase (MnSOD) to hydrogen peroxide, and then to H2O by
catalase or glutathione systems. However, in the presence of excess superoxide
production, O2-. can be converted into peroxynitrite (ONOO.) by nitric oxide (.NO).
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Complex II (Succinate Dehydrogenase), in addition to its function as an ETC protein, is
also a key component of the Krebs Cycle; which through the conversion of the glycolytic
product pyruvate produces substrates for the ETC. This complex utilizes the conversion
of succinate to accept electrons from FADH2 into the ETC. As it is anchored to the inner
half of the IM, there is no translocation of protons from the matrix to the IMS. Complex I
and II transfer their electrons to ubiquinone (CoEnzyme Q10) located within the IM
(Nicholls et al. 2000). These electrons are then passed to Complex III (UbiquinoneCytochrome-C Oxidoreductase) via the Q-cycle, resulting in proton is translocation into
the IMS. Another electron transfer protein, Cytochrome c, accepts this electron and
transports it to Complex IV (Cytochrome-C Oxidase); again translocating a proton into
the IMS via complex IV. It is at Complex IV that oxygen plays its vital role as the final
electron acceptor for the ETC, where it is reduced to form H20. All of the protons that
have been pumped into the IMS create a proton concentration gradient (ΔΨ) which is
utilized by Complex V (ATPsynthase) to facilitate phosphorylation of ADP into ATP for
use as an energy source for cellular processes (Nicholls et al. 2000).

Mitochondrial Dysfunction after TBI
It has become increasingly evident that mitochondrial dysfunction is intimately
involved in the pathology of TBI, as well as the development of other neurological
disorders (Hovda et al. 1992; Verweij et al. 1997; Xiong et al. 1997; Sullivan et al. 1998;
Nicholls et al. 2000; Verweij et al. 2000; Hatton 2001; Pellock et al. 2001; Schurr 2002;
Sullivan et al. 2002; Tieu et al. 2003; Lifshitz et al. 2004; Sullivan 2005; Sullivan et al.
2005). Unfortunately, there is very little we can do to prevent the initial blunt force
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Figure 1.4: Overview of the signaling cascade that follows traumatic brain injury.
Traumatic brain injury has been characterized as a biphasic injury mechanism. Primary
injury is defined as the initial blunt force trauma to the brain tissue. Secondary injury
induces a cascade that begins with the depolarization of the cell membrane by Na+
channel opening, and the subsequent removal of the Mg+ block from NMDA channels.
The activation of these channels results in a large influx of Calcium (Ca++), which is
sequestered into the mitochondria by mitochondrial (membrane dependent) calcium
channels. However, the Ca++ storage capacity is finite, and when it reaches its set point
the mitochondria can be damaged. Mitochondrial damage can result in the production of
reactive oxygen and reactive nitrogen species, which can damage mitochondrial and
cellular components. Large amounts of Ca++ can also activate the formation of the
mitochondrial permeability transition pore (MPTP), which causes the massive efflux of
intramitochondrial proteins and the dissipation of membrane potential (ΔΨ). This cascade
culminates in mitochondrial dysfunction and the initiation of cell death pathways
(apoptosis or necrosis), and ultimately in cell death and neurological dysfunction.
11

trauma that is caused by TBI; however we may be able to intervene within the massive
secondary signalling cascade that can last for hours to weeks following the primary insult
(Figure 1.4). Secondary injury is initiated by a massive depolarization of the plasma
membrane by voltage dependent Na+ channels. Along with glutamate release, this
depolarization causes the removal of the Mg+ block within N-methyl-D-aspartate
(NMDA) channels, causing a massive calcium influx into the cell (Nicholls et al. 1999;
Nicholls et al. 2000; Gunter et al. 2004). This calcium can activate many damaging
cellular enzymes within the cytosol, and as such must be sequestered by the endoplasmic
reticulum and mitochondria (Nicholls et al. 2000; Gunter et al. 2004).
Calcium is transported into mitochondria through a membrane potential-driven
uniporter and is believed to be stored as a calcium phosphate compound within the matrix
(Nicholls et al. 2000). However, the calcium buffering capacity of mitochondria is finite
and eventually the calcium influx becomes too great, resulting in mitochondrial
dysfunction and subsequent initiation of cell death pathways (Brookes et al. 2004;
Lifshitz et al. 2004; Sullivan et al. 2004; Sullivan et al. 2005). Calcium seems to
primarily effect complex I driven respiration, and damage to this major site of electron
acceptance can significantly hinder the ability of the mitochondria to produce ATP (Tieu
et al. 2003; Gunter et al. 2004; Sleven et al. 2006; Maalouf et al. 2007). Importantly, the
loss of adequate membrane potential will cause the ATPsynthase to run in reverse,
thereby dephosphorylating ATP and pumping protons into the IMS in an attempt to
restore membrane potential and preserve mitochondrial homeostasis (Nicholls et al.
2000). However, by depleting ATP stores, energy dependent membrane channels
required to maintain ionic balances will be unable to sustain their function. This causes
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the mitochondria to swell and eventually burst, which are characteristic signs of necrotic
cell death (Nicholls et al. 2000; Sullivan et al. 2005). Calcium overload can also activate
intra-mitochondrial proteins, such as µcalpain, that may contribute to the formation of the
mitochondrial permeability transition pore (mPTP) and release of IM proteins (Scheff et
al. 1999; Nicholls et al. 2000; Garcia et al. 2005; Sullivan et al. 2005).
The formation of the mPTP results in mitochondrial dysfunction and has been
shown to occur after acute TBI (Nicholls et al. 2000; Sullivan et al. 2000; Sullivan et al.
2005). This structure spans both inner and outer membrane, and causes a massive efflux
of calcium into the cytosol and the release of apoptotic inducing proteins, ultimately
leading to cellular loss and cognitive dysfunction (Springer et al. 1997; Nicholls et al.
2000; Sullivan et al. 2000; Nasr et al. 2003; Sullivan et al. 2005; Yu et al. 2007). The
mPTP is a pore comprised of multiple mitochondrial proteins within the inner and outer
membranes, including the adenine nucleotide translocase (ANT), inner and outer protein
transporters (Tim/Tom), voltage-dependent anion channel (VDAC), and Cyclophilin D
(Gunter et al. 2004). It allows nonspecific conductance of matrix and intermembrane
space components to the cytosol, where they can activate detrimental signaling cascades
leading to cell death. One such protein highly involved in both normal mitochondrial
respiration and cell death cascades is cytochrome C. It is normally found in the IMS
electrostatically associated with the P-side of the inner membrane where it shuttles
electrons from complex III to complex IV. However, in the presence of increased calcium
levels it is released from the inner membrane space (Sullivan et al. 2002). After mPTP
opening, it is released into the cytosol where it binds to apoptosis activation factor-1
(Apaf-1), which is also bound to pro-caspase 9. This complex, known as the apoptosome,
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initiates the activation of caspase 3 and subsequent cleavage of apoptotic substrates
ultimately resulting in cellular loss. The opening of the mPTP also releases apoptosis
inducing factor (AIF) and endonuclase G (Endo G), both of which are responsible for
nuclear DNA degradation (Sullivan et al. 1999; Nicholls et al. 2000; Sullivan et al. 2000;
Brookes et al. 2004; Sullivan et al. 2004; Sullivan et al. 2005).
A common byproduct of normal mitochondrial function is the production of
reactive oxygen species (ROS), primarily produced by complexes I and III (Nicholls et
al. 1999; Nicholls et al. 2000; Sullivan et al. 2003; Pandya et al. 2007). Oxygen is the
final electron acceptor of the ECT; however if an electron is accepted by oxygen outside
of the controlled reaction within complex IV, it can result in the production of potentially
damaging radicals that target mitochondrial and cellular structures (Nicholls et al. 2000;
Nicholls et al. 2002; Brookes et al. 2004; Brookes 2005). The Q-cycle of ubiquinone
facilitates the transfer of electrons between complexes, and as such is a highly sensitive
link within the ETC. Under the conditions of high membrane potential electrons become
backed up within the chain and the probability of their escape from the Q-cycle increases
(Nicholls 2002). Rogue electrons first combine with oxygen to form the superoxide
radical (O2.-). As the production of these molecules is a common occurrence,
mitochondria are equipped with endogenous anti-ROS enzymes designed to neutralize
these harmful molecules before they wreak havoc on mitochondrial and cellular systems.
Normally, within the mitochondria, superoxide is converted into hydrogen
peroxide via Manganese Superoxide Dismutase (MnSOD) (Figure 1.3), and subsequently
into water via catalase or glutathione driven antioxidant systems (Patel et al. 2003;
Lambert et al. 2004; Liang et al. 2004; Xiong et al. 2005). However, when the amount of
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superoxide being produced is greater than what endogenous anti-oxidant systems can
manage, they can react with iron or nitrogen to form highly reactive molecules that can
perpetuate damage to mitochondrial and cellular structures (Lambert et al. 2004).
Homozygous MnSOD -/- knockout mice are embryonic lethal and heterozygous MnSOD
+/- knockouts have increased susceptibility to neurological insult, which indicates the
vital function of this gene in physiological function, developmental processes and
neurologic pathology (Patel 2002). Also, overexpression of MnSOD produces lower
amounts of inactive aconitase and 8-hydroxy-2-deoxyguanosine (8-OHdG), measures of
oxidative protein and DNA (most likely mtDNA) damage, indicating a role in the
preservation of mitochondrial function (Patel 2002; Gonzalez et al. 2005; Sleven et al.
2006). The affinity of MnSOD for superoxide is outmatched by its affinity for nitric
oxide (.NO), which combine to form peroxynitrite anion (ONOO.) and then peroxinitrous
(ONOOH); the latter molecule subsequently breaks down into nitrogen dioxide (.NO2)
and hydroxyl (.OH) radicals (Halliwell et al. 2007). Peroxynitrite anion can also combine
with CO2 to form nitrosoperoxocarbanate (ONOOCO2), which then decomposes into
carboxyl radicals (CO3.-) and .NO2. Additionally, superoxide that does manage to be
converted to hydrogen peroxide by MnSOD, can then be converted by iron (Fe2+), present
due to the hemorrhage of blood vessels associated with acute injury, to ferric iron (Fe3+)
and .OH (Fenton reaction, Figure 1.4) (Halliwell et al. 2007). It is the breakdown
products of these reactive oxygen species that have recently been shown to be a major
source of trauma induced oxidative damage to mitochondrial lipids, proteins and DNA
(Sullivan et al. 1999; Sullivan et al. 1999; Hall et al. 2004).
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Recently, it has become more and more apparent that the key to maintaining
cellular and mitochondrial function is to decrease the levels of oxidative stress induced
damage after this excitotoxic calcium influx (Hatton 2001; Sullivan et al. 2004; Singh et
al. 2006). However, because the production of oxidative stress molecules is a normal
byproduct of mitochondrial function and mitochondrial function is required for proper
cellular function, there must be a balance between preserving mitochondrial function and
reducing oxidative damage. In order to properly fuel mitochondrial energy production it
may be necessary to bypass damaged components of the ETC. Therefore, the metabolic
pathways by which you supply the mitochondria become a critical component of the
treatment of TBI.

Fasting & the Ketogenic Diet
Used for centuries as an unproven method for controlling seizure disorders,
fasting causes the body to use stored fats as the primary energy source through the
production of ketone bodies (Thiele 2003; Ziegler et al. 2003). The ketogenic diet (KD)
was developed as a way to get a similar shift of metabolic utilization and increase ketone
bodies without depriving patients of essential nutrients and energy (Stafstrom 1999).
While the underlying mechanism(s) of action remain unclear, the ketogenic diet has been
successfully used in the treatment of medically intractable epilepsy for over eight decades
(Bough et al. 2003; Greene et al. 2003; Tieu et al. 2003; Sullivan et al. 2004; Yamada et
al. 2005; Bough et al. 2006; Bough et al. 2007; Kim et al. 2007; Maalouf et al. 2007). The
regime requires a change in the ratio of fat:carbohydrate consumption from roughly 1:2
to 4:1 (Thiele 2003; Rho et al. 2004). Many versions of the ketogenic diet have been
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examined for efficacy in attenuating seizures, and the method that seems to be the most
effective is a reduced calorie regime coupled with the increased fat:carbohydrate ratio
(Rho et al. 2004). The administration of this diet has been shown to increase levels of
antioxidant enzymes, such as glutathione peroxidase (GPx), and proteins with the ability
to uncouple oxidative phosphorylation from proton transport (UCPs) in order to
transiently decrease membrane potential and ROS production (Sullivan et al. 2003;
Ziegler et al. 2003; Sullivan et al. 2004; Sullivan 2005). It has also been shown to
increase mitochondrial biogenesis in various cell types via fatty acid upregulation
(Totland et al. 2000; Bough et al. 2006).The reduction of ROS and oxidative damage
coupled with preferential utilization of efficient ketone bodies in the brain causes this
treatment to be a very effective therapy for epileptic seizures (Rho et al. 2004). Although
the KD has been highly investigated in terms of epilepsy, the precise mechanism has yet
to be elucidated. However, because the KD and fasting share similar metabolic pathways
it is logical to speculate that they may share similar neurological benefits, and the
elucidation of this fasting mechanism may lead to the development of efficacious
therapies for the treatment of TBI.

Ketones
The primary modulatory target for fasting and the KD is ketosis, or the
upregulation of ketone bodies. Ketones (Figure 1.5), made in the matrix of liver
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Figure 1.5: Structure of β-Hydroxybutyrate, Acetoacetate, and Acetone.
Ketones are produced by the liver in response to low glycolitic stores. The three major
ketones produced are Acetoacetic acid, β-Hydroxybutyrate, and Acetone. βHydroxybutyrate is exported into the blood to the rest of the body. Acetone is mainly
excreted and does not participate in energy production.

mitochondria, normally function to supplement glycolytic substrates for use in cellular
function. Hepatic mitochondria do not have β-oxoacid-CoA transferase; therefore the
liver cannot use ketones for energy production (McKee et al. 2003). This allows ketones
to be exported to the rest of the body for use as fuel. Triacylglycerol (Tg) is a threecarbon alcohol with three fatty acids attached as esters. When intracellular lipases are
activated in response to low glycolitic substrates, Tgs are converted into glycerol and 3
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free fatty acids (FFA) (McKee et al. 2003). The liver then can use these components to
produce ketones from the enzymatic combination of Acetyl-CoA (Figure 1.6). The
primary product of this process is β-hydroxybutyrate (βHB), which is exported to the rest

Figure 1.6: Overview of ketone synthesis and metabolism.
Ketone bodies are produced in the liver in response to low glycolitic substrate levels.
Adipocytes mobilize their triglyceride stores to send glycerol and fatty acids to the liver.
Then the liver produces acetyl Co-A, which it then combines to form acetoacetyl Co-A
using acetoacetyl-CoA thiolase. This is combined with another acetyl-CoA to from
HMG-CoA using HMG-CoA synthase. Acetoacetate is formed by HMG-CoA lyase, and
an acetyl CoA is recycled back into the system. Acetoacetate can then be converted to βhydroxybutyrate through the addition of NADH, and is a reversible reaction. Acetate and
CO2 is also formed. β-hydroxybutyrate is then transported to the brain where it is taken
up by neurons and glia. It is then broken down into acetyl CoA, which is then fed into the
Krebs Cycle to produce substrates for the electron transport chain (ETC). The conversion
of acetoacetate to acetoacetyl CoA by β-Ketoacyl-CoA transferase produces succinate,
which can be fed directly into the ETC.
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of the body for fuel. Upon their uptake into the cell and the mitochondria, βHB is
converted by βHB dehydrogenase into Acetoacetate, which is ultimately converted into
Acetyl-CoA and utilized by the Krebs Cycle (Figure 1.6). However, as a byproduct of
conversion succinate is also produced, which can be directly fed into the ETC (McKee et
al. 2003). Ketone utilization is much more efficient in terms of enzymatic steps and ATP
requirements. Glycolysis uses 11 enzymatic steps and 4 ATP per one molecule of glucose
verses 3 enzymatic steps and 0 ATP per one molecule of βHB (McKee et al. 2003; Prins
2008).

Uncoupling Proteins
The basis of mitochondrial function is that the translocation of protons from the
IMS to the matrix (down their concentration gradient) is coupled to the phosphorylation
of ADP to ATP. Mitochondria are able to create the concentration gradient due to the
function of the electron transport chain (ETC), which creates a potential difference in
proton concentration across the inner membrane via the flow of electrons through a series
of proteins within the ETC. The maintenance of this membrane potential (ΔΨ) is critical
to the proper function of mitochondria, and subsequently cellular function and
homeostasis. However, there is a narrow window in which the mitochondria must keep
the ΔΨ, and deviation from this range can have serious dysfunctional effects on
mitochondrial function and may lead to the initiation of cell death pathways. Increased
ΔΨ will cause a backup of electrons within the ETC, causing an increase in ROS
production, which can damage mitochondrial proteins, lipids, and DNA. Decreased ΔΨ
will cause the reversal of the ATPsynthase, causing it to consume ATP in an attempt to
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recover ΔΨ. This will cause decreased ATP levels within the cell, thereby preventing the
critical function of ion translocators to maintain ionic balance within the cell, which is
especially critical in neuronal function (Nicholls et al. 2000).
Endogenous mitochondrial uncoupling is mediated by members of the uncoupling
protein (UCP) family that dissociate ATP production from the proton translocation in
mitochondria of muscle and fat tissues, leading to heat generation (Nicholls et al. 2000).
UCPs translocate protons across the inner mitochondrial membrane bypassing the ATP
synthase and dissipating mitochondrial ΔΨ (Richard et al. 2001; Nicholls David et al.
2002; Nicholls et al. 2002). This UCP mediated loss of ΔΨ “uncouples” proton pumping
by the ETC from the production of ATP and may lead to subsequent decreases in ATP,
reactive oxygen species (ROS) production, and effect mitochondrial calcium cycling
(Richard et al. 2001; Nicholls David et al. 2002; Sullivan et al. 2003; Sullivan et al.
2004). Their expression and function is believed to be upregulated by fasting and
enhanced by the free fatty acids produced via beta oxidation within the mitochondrial
matrix (Dulloo et al. 2001; Sullivan et al. 2004).
Five mitochondrial UCPs have been identified in the human genome (Dulloo et
al. 2001; Nicholls David et al. 2002; Sullivan et al. 2003). Among these characterized
UCPs, UCP2, UCP4 and UCP5/BMCP1 have recently been shown to be significantly
expressed in the CNS (Horvath et al. 1999; Arsenijevic et al. 2000; Diano et al. 2000;
Kim-Han et al. 2001; Sullivan et al. 2003). However, unlike UCP1 function in brown
adipose tissue (BAT) is to generate heat in cold environments (i.e. thermogenesis), their
physiological role(s) are unclear (Horvath et al. 2003).
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UCP1 was first discovered in the 1960‟s when researchers focused their attention
on the thermogenic capacity of BAT (Nicholls 2001). They were looking, more
specifically, at the mitochondria in BAT to determine the mechanism of fat storage and
mobilization in response to both dietary restrictions and temperature (Nicholls 2001).
Experiments done during this time recognized that BAT stores of lipid substrates could
be mobilized by lipases activated in response to the sympathetic nervous system (SNS)
(Nicholls 2001). It has been proposed that there is a SNS-BAT-UCP axis, which is
modulated by both diet and temperature (Dulloo et al. 2001).
It wasn‟t until the late 1990‟s that researchers found additional UCP1 homologs.
UCP2 was found to be localized ubiquitously throughout the body, and a substantial
amount was found to be localized in various parts of the brain; including the
hypothalamus (suprachiasmatic, paraventricular, dorsomedial, ventromedial nucleus and
arcuate nuclei), brainstem, and limbic system; which suggests that UCP2 plays a role in
neuroedocrine, behavioral, and autonomic functions (Horvath et al. 1999; Richard et al.
2001). This expression had been found to be mainly neuronal; although the identity of the
type of neuron that is participating has been somewhat unclear (Sullivan et al. 2003). It
has recently been accepted that neurons involved in the upregulation of UCP2 possess an
atypical β3 adrenergic receptor that releases noradrenalin in response to SNS signaling,
which activates BAT thermogenesis and liberation of fatty acids (Dulloo et al. 2001;
Nicholls 2001). Highlighting this pathway were studies showing animals treated with a β3
agonist experiencing weight loss associated with UCP expression (Dulloo et al. 2001).
UCP2 knockout animals have an increased ability to secrete insulin, which may suggest a
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role for UCP2 in energy metabolism by functioning as a negative regulator of insulin
secretion (Richard et al. 2001; Erlanson-Albertsson 2002).
UCP3 is primarily found in muscle tissue and BAT, where it plays a role in the
transport of fatty acids across the mitochondrial membrane during fasting or high-fat
feeding when fatty acid oxidation predominates (Dulloo et al. 2001; Richard et al. 2001).
UCP3 knockout animals have been shown to increase the efficiency of ATP production,
decrease in baseline proton leak, increase ROS production, and show an impaired ability
to shift its lipid partitioning between oxidation and storage in response to starvation
(Dulloo et al. 2001). It has also been suggested that both UCP2 and UCP3 achieve their
uncoupling function through the translocation of anions transported across the inner
mitochondrial membrane bound to free fatty acids (Dulloo et al. 2001; Garlid et al. 2001).
Still some others speculate that they transport protons through a pore-like structure
(Garlid et al. 2001). UCP4 and Brain Mitochondrial Carrier Protien-1(BMCP-1 also
called UCP5) have been localized to the brain; however whether they are even UCPs is
still under debate (Dulloo et al. 2001). With the exception of the role of UCP1 in
thermogenesis; all of the UCPs have a sequence homology, although their physiological
role(s) are unclear particular with regard to the CNS.

Mitochondrial UCPs and Ca2+ Buffering
Although the complex mechanisms of secondary neuronal injury are poorly
understood, it is clear that excitatory amino acid (EAA) neurotoxicity plays an important
role (Rothman et al. 1995). Elevated EAAs increase the levels of intracellular Ca2+
([Ca2+]i) by activation of N-methyl-d-asparate (NMDA) receptor/ion channels, -amino-
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3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) receptors and voltage-gated
Ca2+ channels. This results in excessive entry of Ca2+, leading to a loss of cellular
homeostasis and subsequent neuronal Ca2+ overload. Ca2+ is the most common signal
transduction element in cells, but unlike other second-messenger molecules, it is critical
for normal cellular and mitochondrial function. Paradoxically, prolonged high levels of
[Ca2+]i lead to cell death (Choi 1992), however it is required for the activation of specific
glycolytic and Krebs Cycle enzymes (Gunter et al. 2004). Excessive [Ca2+]i can damage
the structure of nucleic acids and proteins and interfere with kinase activity as well as
activating proteases or phosholipases causing cellular damage. Therefore, maintenance of
low [Ca2+]i is necessary for proper cellular function and the initiation of secondmessenger pathway in order to facilitate intracellular communication. Since Ca2+ cannot
be metabolized like other second-messenger molecules, it must be tightly regulated by
cells. Numerous intracellular proteins and some organelles have adapted to bind or
sequester Ca2+ to ensure that homeostasis is maintained. Mitochondria are one such
organelle (Ichas et al. 1998; Rizzuto et al. 1999; Rizzuto et al. 2000).
The mitochondrial membrane potential (), generated by the translocation of
protons across the inner mitochondria membrane via the ETC, culminates in the
reduction of O2 to H2O. This store of potential energy (the electrochemical gradient) can
then be coupled to ATP production as protons flow back through the ATP synthase and
complete the proton circuit. The potential can also be used to drive Ca2+ into the
mitochondrial matrix via the electrogenic uniporter when cytosolic levels increase; and in
turn when cytosolic levels of decrease, Ca2+ is pumped out of the matrix in order to
precisely regulate cytosolic Ca2+ homeostasis (Gunter et al. 1994). During excitotoxic
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insult, Ca2+ uptake into mitochondria has been shown to increase ROS production, inhibit
ATP synthesis and induce mitochondrial permeability transitions (Dugan et al. 1995;
Reynolds et al. 1995; White et al. 1996; Sengpiel et al. 1998; Brustovetsky et al. 2002).
UCP2 has also been shown to play a role in determining the calcium buffering capacity
of the mitochondria, which is a critical factor in maintaining cellular homeostasis
(Richard et al. 2001). It is also important to note that inhibition of mitochondrial Ca2+
uptake by reducing  (chemical uncoupling) following excitotoxic insults is
neuroprotective, emphasizing the pivotal role of mitochondrial Ca2+ uptake in EAA
mediated neuronal cell death (Nicholls et al. 1998; Nicholls et al. 1998; Stout et al. 1998).

Role of Mitochondrial Uncoupling Proteins in ROS Reduction
As noted earlier, free radical production is a byproduct of ATP generation in
mitochondria via the electron transport chain. Electrons escape from the chain and
reduce O2 to O2-.. Normally cells convert O2-. to H2O2 utilizing both manganese
superoxide dismutase, which is localized to the mitochondria, and copper-zinc superoxide
dismutase found in the cytosol. H2O2 is rapidly converted to H2O via catalase and
glutathione peroxidase, but has the potential to be converted to the highly reactive OH
via the Fenton reaction, underlying ROS neurotoxicity. The OH rapidly attacks
unsaturated fatty acids in membranes causing lipid peroxidation and the production of 4hydroxynonenal (HNE) that conjugates to membrane proteins, impairing their function
(Keller et al. 1997; Keller et al. 1997; Mark et al. 1997; Sullivan et al. 1998). Such
oxidative injury results in significant alterations in cellular function. In particular, ROS
induction of lipid peroxidation and protein oxidation products may be particularly

25

important in neurodegeneration (for review see (Mattson 1998)) and TBI (Braughler et al.
1985; Braughler et al. 1989; Braughler et al. 1992; Sullivan et al. 1998).
Mitochondrial ROS production is intimately linked to  such that
hyperpolarization (high ) increases and promotes ROS production (Skulachev 1996;
Skulachev 1998; Votyakova et al. 2001). The underlying mechanism is the altered redox
potential of electron transport chain carriers (reduced) and an increase in semiquinone
anion half-life time (high  prevents bh oxidation of cytochrome b1 in the Q cycle). In
other words, at a high  protons can no longer be pumped out of the matrix (against the
electrochemical proton gradient) by the chain so electron transport slows/stalls resulting
in intermediates staying reduced longer and increasing the chance that the electrons
escape from these intermediates, reducing O2 and increasing ROS production. Since the
magnitude of ROS production is largely dependent on--and correlates with--, even a
modest reduction via increased proton conductance across the mitochondrial inner
membrane (uncoupling) can reduce ROS formation (Skulachev 1996; Kim-Han et al.
2001; Votyakova et al. 2001). Endogenous mitochondrial uncoupling mediated by
members of the UCP family could participate in the reduction of ROS production via this
increased proton conductance. UCPs are activated by FFAs and O2-., and inhibited by
purine nucleotides, indicating that they are sensitive to both ROS and ATP levels (Echtay
et al. 2002) (also see (Harper et al. 2001; Argiles et al. 2002; Zackova et al. 2002) for
review).
Several hypotheses have been put forth concerning possible physiological roles of
the UCPs including energy partitioning, energy balance and control of metabolism which
may be pivotal in obesity and diabetes (Argiles et al. 2002; Jezek 2002). Skulachev was
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the first to hypothesize that mild uncoupling could be beneficial since it causes a decrease
in ROS production (Skulachev 1996). Indeed, several studies have now demonstrated
roles for UCPs in modulating ROS production. UCP2 (Arsenijevic et al. 2000) and UCP3
(Vidal-Puig et al. 2000) knockout mice exhibit increased ROS in macrophages and
muscle, respectively. Leptin-deficient mice have decreased levels of UCP2 and also show
increased ROS production in macrophages (Lee et al. 1999). In vitro overexpression of
UCP2 (Li et al. 2001) or UCP5/BMCP1 (Kim-Han et al. 2001) decrease cell death
following H2O2 exposure and ROS production respectively. Finally our lab has also
reported a neuroprotective role for UCP2 in excitotoxic cell death in vivo (Sullivan et al.
2003). Our findings demonstrate that reducing UCP2 expression and activity, increases
kainic acid induced mitochondrial ROS production and neuronal cell loss in p12 rats
pups, which are classically resistant to excitotoxic insult (Sullivan et al. 2003). UCP2
overexpression has also been demonstrated to reduce ROS production and increase tissue
sparing in vivo following ischemia or TBI (Mattiasson et al. 2003). Together these studies
have implicated uncoupling (possibly via increased UCPs) in a neuroprotective role in
protecting the mitochondria from both increased calcium uptake and increased oxidative
stress (Sullivan et al. 2003).

Peroxisome Proliferator Activating Receptor
Although the exact mechanism remains unknown, UCPs have been suggested to
be upregulated through the activation of the Peroxisome Proliferator Activating Receptor
(PPAR). PPARs are a part of the hormone receptor super family and are mainly involved
in the regulation of lipid metabolism. When activated, these receptors form a heterodimer
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with the retinoid X receptor (RXR) then translocate into the nucleus where they bind to
peroxisome proliferator response elements (PPRE); thereby initiating the transcription of
specific enzymes involved in lipid homeostasis (Staels et al. 1997; Pineda Torra et al.
1999; Debril et al. 2001; Kiec-Wilk et al. 2005). As of now, three isoforms have been
identified which seem to be involved in opposing pathways of lipid homeostasis. PPARγ,
which is highly expressed in adipose tissue, is responsible for the differentiation of
adipocytes and its expression is acutely induced by insulin (Debril et al. 2001). It
functions primarily in lipogenesis and storage of lipids in adipocytes and other tissues. Its
expression is upregulated by caloric restriction and is activated by certain naturally
occurring FFA derivatives and a synthetic agonist thiazolidinediones (DZT), which is
mainly used as a therapy for insulin resistance in diabetes (Debril et al. 2001; Shi et al.
2005). Its activation has been shown to increase high density lipoprotein (HDL) while
reducing triglycerides; however this can come at a great risk due to the chance of
increased levels of low density lipoprotein (LDL) created during the conversion of very
low density lipoprotein (VLDL) to HDL, so it is likely that long term use may not be
beneficial (Staels et al. 1997; Staels et al. 1998; Debril et al. 2001; Staels et al. 2005).
PPARα, which was the first of the isoforms to be identified and cloned, is mainly
found in tissues which have a high metabolic rate for fatty acids (FA) such as liver, BAT,
kidney, heart, brain, and skeletal muscle and is involved in a divergent pathway in lipid
metabolism responsible for initiating the transcription of genes that are involved in the
transport of FA into cells/mitochondria and in the subsequent oxidation of those FAs
(Staels et al. 1997; Cullingford et al. 2002; Feinstein 2003; Shi et al. 2005). This isoform
of PPAR is activated by fibrates (such as Ciprofibrate and Wy-14643) due to their dialkyl
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fibrate head group which makes them highly selective for binding of the α isoform
(Cullingford et al. 2002). Fibrates are used as an effective therapy for the reduction of
high LDL cholesterol and triglyceride levels and the subsequent increase in HDL
cholesterol levels due to the upregulation of apoA-I/II (Staels et al. 1997; Staels et al.
1998; Pineda Torra et al. 1999; Staels et al. 2005). These PPARα specific ligands also
reduce apoC-III and apoB expression which inhibit the removal of LDL and VLDL
(Staels et al. 1997; Staels et al. 1998; Shi et al. 2005). The PPARα isoform can also be
activated by certain long chain FFA (i.e. α-linoleic acid and oleic acid) which have been
described as natural ligands (Pineda Torra et al. 1999; Westin et al. 2004). PPARα has
been shown to decrease pro-inflammatory FFA (i.e. lipid peroxides) as well as increasing
mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (mHS) expression (Pineda
Torra et al. 1999; Cullingford et al. 2002). This hepatic enzyme (mHS) is the key initiator
of the conversion of acetyl-CoA, derived from FA, into ketone bodies (βHB and ACA).
PPARα activation induces the transcription of many enzymes involved in the import and
β-oxidation of triglycerides and FA (Staels et al. 1998; Kashiwaya et al. 2000). It has
been implicated in an anti-inflammatory role since PPARα can directly interfere with
NFκB transactivation by binding co-activator protein p65; however this sequestration
does not inhibit all of NFκB-driven transcription products (Tan et al. 2005). This may be
important in light of the evidence that TNFα, which is an activator of NFκB and
ultimately MnSOD, knockout mice have decreased tissue sparing after a focal CCI injury
(Sullivan et al. 1999). Activation of PPARα may lead to discriminatory inhibition of
NFκB-driven transcription of pro-inflammatory cytokines, while leaving the pro antioxidant mechanism in place and inducible in response to TBI.
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Both PPARs and UCPs are sensitive to FFA modulation and induction of
function. FFAs act as natural PPAR ligands to activate target genes, and also play a role
in modulating the activation of those target genes at a transcriptional level (Staels et al.
1997; Pineda Torra et al. 1999; Kashiwaya et al. 2000; Westin et al. 2004; Kiec-Wilk et
al. 2005; Shi et al. 2005). In addition to inducing the upregulation of UCPs via PPAR
activation, FFA activate UCPs; however it is still undetermined whether they induce a
proton pore or if they utilize the membrane protein to translocate (flip-flop) proton ions
across the inner membranes (Figure1.7) (Klingenberg 1999; Garlid et al. 2001). Our
preliminary data have found that UCPs are upregulated during fasting, which could
implicate PPARs as players in metabolic homeostasis (i.e. ketogenesis) as well as a
neuroprotective mechanism due to their involvement in UCP upregulation. The
elucidation of this mechanism could result in novel therapeutic treatment applications for
TBI.

Figure 1.7: Proposed mechanisms of UCP mediated proton translocation.
There are two proposed mechanisms of UCP mediated proton translocation, which can
uncouple the electron transport chain from ATP production. The first proposed
mechanism states that free fatty acids (FFA) use UCPs as a platform so that they can
become protonated and flip-flop across the inner membrane (left side of figure). The
second is that they activate UCPs, which then form a pore through which protons can
then flow (right side of figure). Both of these mechanisms require the presence of
reactive oxygen species, and as such have been described as an endogenous anti-ROS
mechanism.
Copyright © Laurie M. Davis 2008
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Chapter 2
The Neuroprotective Effect of Fasting after TBI: Possible Mechanism(s) and
Clinical Implications
Introduction
Mitochondria have recently been implicated as a critical component of cellular
regulation and homeostasis. Ordinarily, mitochondria maintain cellular homeostasis
through their vital role in Ca2+ sequestration and the production of ATP (Sullivan et al.
1998; Nicholls et al. 2000; Sullivan et al. 2002; Brookes et al. 2004). Mitochondria are
also the communal mediator in the activation of cell death pathways; in effect acting as
the "death switch" of the cell (Sullivan et al. 2005). As such, it seems reasonable to
speculate that the preservation of normal mitochondrial function after TBI would
alleviate the cellular stresses of secondary injury, and may result in improved post-injury
cognitive outcome. This concept has gained much credibility in recent years due to a
number of experimental studies showing that such treatment strategies aimed at
maintaining normal mitochondrial function are neuroprotective (Sullivan et al. 1998;
Scheff et al. 1999; Lifshitz et al. 2004; Sullivan et al. 2004; Sullivan 2005).
Extrapolating from such findings one might ask how improved mitochondrial
function might be achieved clinically? Previous studies have shown that fatty acids
increase mitochondrial biogenesis in skeletal muscle, heart, liver (Totland et al. 2000)
and in brain (Bough et al. 2006). These observations suggest that a high-fat diet may
ameliorate mitochondrial dysfunction in humans. One such diet designed to achieve a
high fat to carbohydrate ratio paradigm is the anti-epileptogenic ketogenic diet. This
dietary therapy was originally designed to mimic the physiological effects of fasting, and
most notably produces mild hypoglycemia and systemic ketosis. While the underlying
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mechanism(s) of action remain unclear, the ketogenic diet has been successfully used in
the treatment of medically refractory epilepsy for over eight decades (Bough et al. 2003;
Greene et al. 2003; Tieu et al. 2003; Sullivan et al. 2004; Yamada et al. 2005; Bough et
al. 2006; Bough et al. 2007; Kim et al. 2007; Maalouf et al. 2007). Interestingly, ketone
bodies appear to exert direct neuroprotective effects in a variety of in vivo and in vitro
models (Bough et al. 2003; Tieu et al. 2003; Sullivan et al. 2004; Yamada et al. 2005;
Kim et al. 2007; Maalouf et al. 2007). For example, when administered after MPTP, a
mitochondrial toxin used in an experimental models of Parkinson‟s disease, betahydroxybutyrate (βHB) enhances mitochondrial respiration and prevents neuronal injury
(Tieu et al. 2003). Also, we have previously shown that ketone bodies raise the threshold
for induction of the mitochondrial permeability transition (Kim et al. 2007). Given these
findings, we hypothesized that fasting will produce a neuroprotective effect in a
controlled cortical impact (CCI) model of TBI, possibly through ketone body production.
In the present study, we found that fasting improved tissue sparing, cognitive
function, and limited mitochondrial dysfunction when implemented post injury. To
elucidate the underlying mechanism of fasting-induced neuroprotection, we modulated
metabolic effects of fasting independently. To this end we found that after moderate TBI,
ketone administration, but not acute insulin mediated hypoglycemia, exerted a significant
neuroprotective effect. We also found that ketones alleviated mitochondrial dysfunction
after excitotoxic calcium insult. Collectively, our study highlights a possible clinical
implication for treatment, and underscores the importance of metabolic regulation after
TBI.
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Methods
Animals
All experimental animal procedures were approved by the Animal Care and Use
Committee at the University of Kentucky. All experiments were conducted using adult
male Sprague-Dawley rats (250-300g), which were housed 3 per cage and maintained in
a 12-hour light/12-hour dark cycle. All animals were fed a balanced diet ad libitum unless
otherwise specified.

Surgical Procedures and Experimental Paradigms
All surgical procedures were performed as previously described under 2%
Isoflurane (Sullivan et al. 1998; Sullivan et al. 1999; Sullivan et al. 2000) Injuries were
classified as moderate (1.5mm) or severe (2.0mm), based on the specified depth of
mechanical cortical depression. To investigate the neuroprotective effect of fasting after
TBI, animals were given a controlled cortical impact (CCI) of either a moderate or severe
injury and were either fed ad libitum or fasted for 24 or 48 hours (3 groups n=5/group).
Animals were allowed free access to water during the fasting time, and after fasting were
fed ad libitum. Body temperature was maintained at 37°C throughout the experiment
until the animals were awake and moving freely about their cage. Behavioral testing (see
below) was performed beginning 10 days post injury and tissue harvesting for tissue
sparing assessment was done at 15 days post injury. As a 24hr fast after moderate CCI
injury was the only paradigm that was found to be neuroprotective, this was the only
injury level and fasting duration examined in the remainder of our studies. In a separate
set of animals, blood glucose and ketone levels were monitored by first anesthetizing
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animals with 2.0% Isoflurane followed by tail prick blood extraction. Ketone levels were
measured using a STAT-Site® analyzer (Stanbio Laboratory, Boeme, Texas). Glucose
levels were measured using Therasense™ (Freestyle) glucose meter. To determine if TBI
+/- fasting had an effect on ketone or glucose levels a separate set of animals received a
1.5mm injury, however only one of the groups was fasted for 24 hours; glucose and
ketone levels were taken at 0, 3, 6, and 24hrs (Table 2.2, 2 groups 3/group).
An alternate group of animals were fasted or injected with either saline, 5U, 10U
insulin (Humulin®R regular Eli Lilly and Co. Indianapolis, IN 46285), after which
glucose and ketone levels were taken at -5min, 1hr, 3hr, 6hr, and 24hr (Table 2.1, 4
groups, 3/group). After determining the proper insulin dose, animals received a 1.5mm
CCI injury and were injected with a 10U dose of insulin at 3, 6, 9, 12, 15, and 21 hrs post
injury (7 groups 4/group). Animals were sacrificed at 7 days post injury at which time
tissue preparation and tissue sparing assessments were performed.
To investigate the neuroprotective effect of exogenous ketone administration, a
separate set of animals were given a 1.5mm CCI injury and administered D-βHB via
mini-osmotic pumps at a constant dose of either of 1.66 mMoles/kg/day (n= 6), 0.83
mMoles/kg/day of D-βHB (n=10) (Sigma-Aldrich Co St. Louis, MO 63178) or saline
(n=10). The pumps were subcutaneously inserted immediately after injury and removed
after 3 days. Animals were sacrificed 10 days post injury at which time tissue preparation
and tissue sparing assessments were performed.
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Tissue Preparation, Histology and Tissue Sparing Assessments
All animals were sacrificed and their tissue prepared as previously described
(Sullivan et al. 2000). Briefly, all animals were anesthetized by administering a 95 mg/kg
dose of sodium pentobarbital (Nembutal, Abbott Laboratories, Chicago, IL) and
subsequently transcardially perfused using phosphate-buffered saline (PBS) followed by
PBS (pH 7.4) containing 4% paraformaldehyde (PFA). Brains were extracted and stored
in a PBS solution containing 4% PFA and 15% sucrose at 4ºC for at least 24hrs until
sectioning could be performed. Brains were coronally sliced on a freezing microtome at a
thickness of 50µm. Sections were mounted on gelatinized slides and stained with Cresyl
Violet. Slides were viewed using an Olympus AX70 microscope at 4X power and images
were taken using an Olympus MagnaFire (model S99800) U-TVO .5XC camera. Tissue
sparing was measured with Image J (NIH freeware) software (Michel et al. 1988;
Sullivan et al. 1999; Sullivan et al. 2000; Pandya et al. 2007) . The cortical volume of
each brain was measured by separately tracing the outline of the ipsilateral and
contralateral cortex in 12 sections from each brain. The sections were taken 250um apart
from anterior to posterior. The volume of ipsilateral tissue spared was compared to the
volume of tissue contralateral to the injury and results were expressed in % tissue spared
(ipsilateral/contralateral*100) (Figure 2.1).
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Figure 2.1: Cavelleri method of tissue sparing assessment.
Tissue sparing is calculated tracing the volume of the cortex of 12 sections from each
animal. Then we determined the percent tissue spared by dividing the ipsilateral area (A)
by the contralateral area (B) and multiplying by 100 to get the percentage of spared
tissue. (A/B*100). Figure shows both and injured and naïve section from similar
anatomical locations.

Behavioral Testing
Sham operated or animals which underwent a moderate TBI and either were
fasted for 24 hrs, fed ad libitum were behaviorally assessed using a well characterized
adaptation of the Morris Water Maze (MWM) to assess cognitive function at 10 days post
TBI (Scheff et al. 1997; Verbois et al. 2003; Pandya et al. 2007). During these
assessments the animals were tested for goal latency, target quadrant entries, target search
time, swim speed and target annulus crossings as a measure of spatial learning and
memory. The maze consisted of a darkened (nontoxic black powder pain) circular pool of
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water (121cm across, 56cm high, 30cm deep) at 27 C. Just beneath the water (2cm), a
Plexiglas platform was placed and used as the goal platform for targeting 40 cm from the
side of the pool. The entire pool was in a 4m x 4m room with consistent extra-maze cues,
and placed directly beneath a video camera that recorded swim performance. These video
recordings were analyzed by a video motion analyzer (Videomex V, Columbus
Instruments, Columbus, OH). Testing began 10 days post injury and continued for a total
of 5 consecutive days. Early motor deficits that are occasionally seen within the first few
days after injury will not confound our results because we are delaying behavioral
assessment for 10 days post injury. Each day animals were separately placed in a
randomized quadrant (north, south, east, west) of the pool facing the wall and each
animal was allotted 120 seconds to locate the hidden platform. If the animals were unable
to locate the platform they would be manually placed on the platform from 30s and
subsequently placed in a heated incubator for 4 minutes between trials. In order to rule
out nonspecific visual deficits animals were tested using a visible platform (2.0 cm above
water) following transfer testing. Animals that failed to reach the platform during this
testing paradigm were removed from the behavioral pool of data as this indicates that
they are unable to see properly and therefore cannot use the designated visual cues. To
asses swim speed used the mean of the total path length and latency to reach the platform
during the four trials/day. On the last day of testing after the latency trials were
completed, a probe trial was performed in which the platform was removed from the pool
and the animal was allowed to search for 60 seconds. In order to assess how well the
animal learned where the target platform (annulus) was located, target annulus crossings,
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target search time, and target quadrant entries (expressed as a percentage of total quadrant
entries) were used as endpoint measurements. (3groups n=5/group)
Mitochondrial Isolation
These procedures are based on, and contain, modifications of previously
described protocols (Brown et al. 2004). A separate set of animals received a moderate
TBI injury and were either fasted for 24hrs or fed ad libitum. At 24hrs post injury the
brains of adult male Sprague-Dawley rats (~250g) were quickly removed and a 5mm
punch of the injured cortex was dissected and removed. Cortical tissue was placed in cold
isolation buffer with 1mM ethylene glycol tetraacetic acid (EGTA) (75mM sucrose,
215mM mannitol, 0.1% BSA, 20 Mm HEPES with a pH of adjusted to 7.2 using KOH).
Tissue was homogenized and spun at 1,300 x g for 5 minutes at 4ºC. The supernatant was
taken off and saved in separate tubes. The pellet was resuspended and spun at 1,300 x g
for 5 minutes at 4ºC. The supernatant was again taken off and saved in separate tubes.
The saved supernatant was spun at 13,000 x g for 10 minutes at 4ºC. The pellets were
resuspended and a nitrogen bomb was used to rupture the cell membrane (Brown et al.
2004). After bombing, the sample was separated on a Percoll gradient via centrifugation
in a high speed Sorval centrifuge for 10 minutes at 30,400 x g. The third fraction
containing the purified mitochondria was removed and spun at 16,700 x g for 15 minutes.
The pellet was resuspended and spun at 13,000 x g for 10 minutes. The pellet was
resuspended in 500μL isolation buffer without EGTA and transferred to a
microcentrifuge tube, which was then spun at 10,000 x g for 10 minutes. The supernatant
was removed and the pellet was resuspended in enough isolation buffer without EGTA to
obtain a concentration of 10-15ug/μl. BCA protein assay kit was used determine protein
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concentration by measuring absorbance at 560 nm with a BioTek Synergy HT plate
reader (Winooskin, Vermont).
Mitochondrial Respirations
Mitochondria isolated from punches of injured cortex were suspended in KCl
respiration buffer (125mM KCl, 2mM MgCl, 2.5mM KH2PO4, 20mM HEPES, 0.1%
BSA) inside a sealed constantly stirred thermo-regulated Oxytherm chamber containing a
Clark-type oxygen electrode as previously described (Brown et al. 2004). Substrates were
added (Pyruvate (5.0mM)/Malate (2.5mM), ADP (150μM) oligomycin (2μm), FCCP
(1µM), Rotenone (0.8µM), succinate (150µM)) to determine the functionality of the
mitochondria at various states (Brown et al. 2004). (n=4/group)
For respirations done in the presence of Ca2+, mitochondria were isolated from
whole cortex (from naïve animals), rather than a punch. KCl stock respiration buffer (as
described above) also containing 5mM Pyruvate and 2.5mM Malate was used to for
respiration studies. A final concentration of 0.5mM calcium was added to one aliquot of
stock buffer. Ketones (final concentration of 1mM D-βHB and 1mM ACA) were added
to the stock buffer with and without 0.5mM calcium. 250uL of buffer was added to the
oxytherm chamber along with mitochondria from naïve unfasted animals. Respirations
were conducted as described above. (n=4/group)
Oxidative Biomarkers
A separate set of animals were used to measure oxidative biomarkers. In these
studies animals were given a moderate CCI injury and either fasted for 24hrs or fed ad
libitum. At 24hrs post injury, the mitochondria from the injured site were isolated and
assessed for oxidative damage markers. (n=6/group)
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Protein Damage Assessment
Mitochondrial protein oxidation was assessed by measuring protein carbonyls
using the OxyBlot Protein Oxidation Detection Kit (OxyBlot, Intergen Company,
Purchase, New York) as previously described (Pandya et al. 2007). Breifly,
mitochondrial samples taken from a 5mm punch of the injury site of fasted and unfasted
injured animals isolated at 24 hours post injury were derivatized with 2,4dinitrophenylhydrazine (DNP) to achieve the formation of 2,4-dinitrophynylhydrazone.
Samples were then neurtralized and separated by gel electrophoresis. After transfer, the
membrane was incubated with primary antibody to detect protein carbonyl groups
through the binding to a specific DNP moiety. This incubation was done overnight at
4°C, after which the membrane was sufficiently rinsed with wash buffer (phosphate
buffered saline, 0.2% Tween-20). The membrane was then incubated with a goat-antirabbit HRP-conjugated secondary antibody, and subsequently developed using enhanced
chemiluminescent (ECL) detection solutions (Amersham-Pharmacia, Piscataway, NJ).
Bands were quantified using densitometry using a Molecular Dynamics Storm 860
phosphoimager and NIH Image software. (n=6/group)
Lipid Peroxidation Assessment
The mitochondrial lipid peroxidation assessment was performed using a slot blot
technique as previously described (Pandya et al. 2007). Breifly, mitochondrial samples
taken from a 5mm punch of the injury site of fasted and unfasted injured animals were
isolated using a protease inhibitor cocktail (Sigma) isolation buffer and subsequently
flash frozen using liquid nitrogen. Using a Pierce BCA protein concentration kit, 250ng
of solubilized mitochondrial protein was loaded to each slot blot well. Under a vacuum
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the samples were transferred to a nitrocellulose membrane. This membrane was
incubated with primary anti-4-hydroxynonenole (HNE) antibody (monoclonal 1:2500,
Chemicon). After washing, the membrane was incubated with rabbit-anti-mouse antibody
HRP-conjugated secondary antibody, and subsequently developed using ECL solutions
(Amersham-Pharmacia, Piscataway, NJ). Band densities were assessed using afore
mentioned imager and software. (n=6/group)
Mitochondrial In Situ Ca2+ Load Assessment
In order to assess mitochondrial Ca2+ cycling/loading in situ, we used a novel
technique developed by our lab as previously reported (Pandya et al. 2007). Breifly,
animals were sacrificed and perfused with cold buffer containing Ca2+ uniporter
inhibitors (0.6µM ruthenium red), Ca2+ antiporter inhibitors (10µM CGP-37157 and
0.6µM ruthenium red), and mPTP inhibitors (5µM cyclosporin A). This “locking” buffer
is designed to prevent the loss of Ca2+ during the mitochondrial isolation process. Brains
were removed and a 5mm punch of the ipsilateral cortical injury site was dissected from
injured fasted and injured unfasted animals, which was placed in “locking” isolation
buffer containing the above described additions. One important difference between the
locking isolation buffer and isolation buffer described previously is the lack of EGTA in
the buffer throughout the isolation procedure. Ca2+ levels were assessed using Calcium
Green 5N, which is a non membrane permeable indicator with excitation at 485nm and
emission at 528nm. Mitochondrial samples were measured for fluorescence before and
after the addition of 10% DMSO, which causes the release of intra-mitochondrial Ca2+. A
standard curve of Ca2+ fluorescence was used in order to extrapolate our values to molar
Ca2+/mg protein. Values were then expressed as a percentage of unfasted injured calcium
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loading levels from fasted injured mitochondria. All assays and standards were performed
using identical total volumes. (n=6/group)
ROS Assay
Mitochondrial samples were assessed for ROS production using the permeative
indicator 2′-7′-dichlorodihydro-fluorescein (DCF) as described previously (Sullivan et al.
2003). Briefly, isolated mitochondria were incubated in respiration buffer at 37◦C in the
presence of horseradish peroxidase (1g/ml) and DCF (10M) and measured using a
fluorometric plate reader (excitation 485 nm, emission 528 nm). Fasted mitochondria
were compared to mitochondria isolated from unfasted (control) animals and the
fluorescence was expressed as a percentage of the control fluorescence (fasted
value/control value *100). (n=6/group)
Calcium ROS/NADH Assay
ROS and NADH were measured using a Synergy HTTR com1 plate reader and
analyzed using KC4 software program (Bio-Tek Instruments Winooski, VT). A KCl
stock respiration buffer (as described above) which also contained 5mM Pyruvate,
2.5mM malate, 10μM DCF, and 100μM HRP was used to measure fluorescence. A final
concentration of 0.5mM calcium was added to one aliquot of stock buffer. Ketones (final
concentration of 1mM D-βHB and 1mM ACA) were added to the stock buffer with and
without 0.5mM calcium. 25μg of protein was added to each well containing 50μL total
volume of one of the previously described buffers. ROS production was measured at
37˚C at 485nm/528nm and NADH auto-fluorescence was measured at 360nm/460nm for
15 minutes at intervals of 1:24 minutes. Values from blank wells containing only buffer
were subtracted from values obtained from sample wells. Groups were Ketones, Calcium,
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and Ketones + Calcium (n=8/group). Values were expressed as % control (mitochondria
with calcium free and ketone free buffer).
Statistical Analysis
For all statistical comparisons, significance was set at p < 0.05. Data were
evaluated using analysis of variance (ANOVA) or unpaired t-tests when appropriate.
When warranted by the ANOVA, post hoc comparisons employed the Student-NeumanKeuls and Bonferroni post hoc analyses, respectively.

Results
Fasting is Neuroprotective after Traumatic Brain Injury
In this study, we found that the amount of cortical tissue sparing increased when
animals were fasted for 24 hrs after a moderate (1.5mm) injury compared with unfasted
injured animals (Figure 2.2). In contrast, 48 hrs of fasting post injury did not result in a
significant increase in tissue sparing following a moderate injury, suggesting no additive
effect for a prolonged fasting period (Figure 2.2). The neuroprotective effect of fasting
was also lost after a severe (2.0mm) injury in both fasting paradigms (Figure 2.3).
Cognitive function was significantly lower in unfasted injured animals, indicated by
increased goal latency, decreased search time, annulus crossings, and target search time
(Figure 2.4 B). However, fasted injured control animals had significantly improved
scores on all of the aforementioned measures of cognitive function; which also were not
significantly different from sham operated animals (Figure 2.4 B). Interestingly, fasted
injured animals were not significantly different than sham animals in terms of goal
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Figure 2.2 Fasting increases tissue sparing after moderate (1.5mm) CCI injury.
(A) Animals fasted for 24hrs after a moderate (1.5mm) CCI injury showed a significant
increase in tissue sparing compared with control animals, which were continually fed ad
libitum after TBI. Fasting animals for 48hrs did not show a significant amount of tissue
sparing compared with control injured animals. Values are shown in percent contralateral
volume. (n=5/group; ANOVA p<0.05, F2, 14=5.6, R2=0.48 *p<0.05 ± SD). (B) Shows a
representative section from each treatment group a similar anatomical location within
serial sectioning..
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Figure 2.3 Fasting is unable to increase tissue sparing when administered after
severe (2.0mm) CCI injury. When animals received a 2.0mm injur, fasting did not
significantly increase tissue sparing when administered for either 24hr or 48hrs after
injury. Values expressed as percent of contralateral cortex (n=5/group; ANOVA p>0.05
F2, 14=0.16, R2=0.026, ± SD).
latency; however they did show a significant difference compared to unfasted injured
animals a 12 and 15 days post injury (Figure 2.4 A). Swim speed was not significantly
different between any of the groups, indicating that physical limitations induced by the
injury did not influence behavioral outcome (Figure 2.4B).

Fasting Reduces Mitochondrial Damage and Improves Function after TBI
Our studies also demonstrate that fasting after injury reduces the levels of several
biomarkers of mitochondrial dysfunction and cellular damage including mitochondrial
ROS production and Ca2+ loading, and to a lesser extent, protein carbonyls and lipid
peroxidation (Figure 2.5). Mitochondria isolated from the injury site of fasted animals
showed significantly higher ADP utilization (i.e., state III) rates when compared to
mitochondria isolated from unfasted injured animals (Figure 2.6). Collectively, these
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A.

B.

Figure 2.4 Fasting improves cognitive recovery after moderate (1.5mm) CCI injury.
(A) Behavioral testing, using an adaptation of the Morris Water Maze, showed that
injured unfasted animals showed significantly increased latency compared with sham
animals. Fasted injured animals did not show a significant difference in goal latency
compared with sham animals. (n=5/group; Two-Way Repeated Measures ANOVA
p<0.05 F2,48=12, *p<0.05 **p<0.01 ***p<0.001 compared to No Fast (unfasted injured)
animals, ± SD). (B) Fasted injured animals did not perform significantly differently
from sham (unfasted) animals. However, injured unfasted animals did show significant
differences in target quadrant entries (% of all quadrant entries) (F2, 14=8.3, R2=0.58),
target search time (seconds) (F2, 14=8.2, R2=0.58), and target annulus crossings (F2, 14=13,
R2=0.69) when compared with sham unfasted and fasted injured animals. There was no
significant difference between the treatment groups for swim speed (F2, 14=1.0, R2=0.15),
indicating that the behavioral results were not influenced by physical limitations due to
injury (n=5/group; ANOVA * p<0.05 compared with injured unfasted animals, ± SD).
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data indicate that 24hrs of fasting post injury induces a beneficial mechanism for
preservation of mitochondrial and therefore cellular function after TBI and, unlike other
neuroprotective treatments such as creatine or some antioxidants (Sullivan et al. 2000),
has the advantage of post injury administration.
As our data indicate, the optimal time point and injury level for intervention
would be a 24hr post injury suspension of caloric intake following a moderate (1.5mm)
TBI. Therefore, this was the paradigm we employed to elucidate a mechanism underlying
the neuroprotective effects of post-injury fasting.

Figure 2.5: Post Injury fasting reduces biomarkers of injury.
Mitochondria from fasted injured animals showed a significant decrease in the
biomarkers of damage compared with mitochondria from unfasted injured animals. Total
calcium load, measured using locking buffer to block the efflux/influx of calcium during
preparation, was decreased in fasted animals indicating a decrease in the TBI induced
dysfunction of calcium cycling. Decreased ROS levels, indicative of decreased oxidative
stress, combined with decreased markers of protein and lipid damage indicate that fasting
decreases both oxidative stress and subsequent oxidative damage resulting from TBI
(n=6/group; unpaired t-test, t10= 4.8 (Ca2+ Loading), t10= 7.6 (ROS Production) , t10= 4.4
(Protein Carbonyls), t10= 2.8 (Lipid Peroxidation) *p<0.05 ± SD).
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Figure 2.6: Fasting increases mitochondrial function after TBI.
Injured unfasted animals had no dietary modulations after CCI injury, whereas animals in
the injured fasted treatment group were fasted for 24hrs post CCI. Mitochondria isolated
from these punches at 24hrs post injury were monitored for oxygen consumption in
response to mitochondrial substrates. The mitochondria from fasted injured animals
showed significant increases in their ability to utilize ADP for ATP production (State III).
The designations for state 3a (t4=4.4) and 3b (t4=6.3) are due to the order they were
performed in. State 3b should be slightly higher than state 3a, due to the priming of the
ETC and Krebs cycle state 3a. (Unpaired t-test; * p <0.05 n=3/group ± SD, one animal
from each group was dropped because they were more than 2 SD from group mean.)

Insulin and Ketone Administration after Injury
It is widely known that fasting induces many metabolic changes, including
modulation of blood glucose and ketone levels (Burge et al. 1993). Naïve fasted animals
monitored for glucose and ketone (βHB) levels showed simultaneous, significant
decreases in glucose and increases in ketone levels after 24hrs compared with naïve
unfasted animals (Table 2.1). Additionally, fasted injured animals show a significant
decrease in glucose levels and an increase in ketone levels when compared with unfasted
injured animals, indicating that fasting is modulating metabolism in ways that injury
alone does not, and that unfasted animals return to normal eating habits after injury
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(Table 2.2). These data present two possible underlying mechanisms of fasting-induced
neuroprotection, namely, hypoglycemia and ketosis. To evaluate each of these
possibilities, we independently modulated ketone and glucose levels in unfasted animals
and assessed their effects on tissue sparing following a moderate TBI. Hypoglycemia was

A)
Glucose
(% -5 min)

-5 min

1hr

3hr

6hr

24hr

103.72±28.51

82.61±18.21

89.41±17.63

0U

100.00±41.97 88.16±36.16

5U

100.00±57.01 50.18±16.05 35.59±8.89**,##

93.80±34.43

109.23±44.56##

10 U

100.00±28.51 49.59±15.45

47.02±19.34**

78.53±13.82

83.20±5.56

Fasted

100.00±21.71 91.03±11.06

84.78±11.62

89.06±13.56

47.22±9.87*

* p<0.05 compared with 0U; ** p< 0.01 compared with 0U
## p<0.01 compared with fasted
B)
β-HB
(mM)

-5 min

1hr

3hr

6hr

24hr

0U

0.068±0.06

0.130±0.15

0.200±0.10

0.100±0.10

0.000±.0.00

5U

0.033±0.06

0.230±0.12

0.067±0.16

0.067±0.06

0.000±0.00

10 U

0.200±0.17

0.170±0.06

0.100±0.10

0.000±0.00

0.000±0.00

Fasted

0.100±0.00

0.000±0.00

0.033±0.06

0.100±0.10

1.030±0.06$

$ p<0.001 compared with 0U, 5U, and 10U
Table 2.1: Insulin Administration Decreases Glucose Levels without Affecting
Ketone Levels in Naïve Animals.
(A) Insulin artificially decreases glucose levels to 24hr fasting levels at 3hrs post
injection (n=3/group; 2-way ANOVA p<0.05, F3, 32=2.5; Bonferroni post test; * p<0.05
compared with 0U; ** p< 0.01 compared with 0U; ## p<0.01 compared with fasted, ±
SD). (B) Ketones (βHB) were not increased in response to insulin administration. Fasting
significantly increased ketone levels after 24hrs compared with 0U, 5U, and 10U.
(n=3/group; 2-way ANOVA p<0.05, F3, 32=21, Bonferroni post test; $ p<0.001 compared
with 0U, 5U, and 10U; ± SD).
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A)
Glucose

0hr

3hr

6hr

24hr

Fasted Injured

100.0±10.94

110.2±6.78

119.9±27.87

86.7±8.67*

Unfasted Injured

100.0±30.45

96.3±4.67

131.4±33.04

124.58±7.24

% 0hr (Control)

* p<0.05 compared with unfasted injured animals.
B)
β-HB (mM)

0hr

3hr

6hr

24hr

Fasted Injured

0.23±0.15

0.4±0.19

0.33±0.12

0.57±0.06**

Unfasted Injured

0.27±0.12

0.07±0.06

0.13±0.06

0.27±0.06

** p< 0.01 compared with unfasted injured animals.
Table 2.2: Fasting induced modulation of glucose and ketone levels after moderate
(1.5mm) controlled cortical impact (CCI) injury.
(A) Fasted animals showed a significantly decreased level of serum glucose at 24hrs post
injury compared with injured unfasted animals (Paired t-test, t2, 11=31.27 * p<0.05
compared with unfasted injured animals). (B) Fasting animals after injury induced
significantly higher levels of ketones at 24hrs post injury compared with unfasted injured
animals; (Paired Student‟s t-test, t2, 11=5.29 ** p< 0.01 compared with unfasted injured
animals 5). (n=3/group ± SD).

induced using insulin administration, due to its ability to artificially decrease blood
glucose levels without altering ketone production (Table 2.1). Based on our preliminary
dosing studies (Table 2.1), insulin was administered at different time points after a
moderate injury, throughout which animals were fed ad libitum. Assessment of cortical
tissue sparing showed no significant sparing of tissue with any of the insulin injection
time points. In fact, insulin administration at 3, 15, and 21hrs resulted in an increased
mortality rate (Figure 2.7). These treatment groups were excluded from the ANOVA
analysis due to the high mortality. Although we have used an acute insulin administration
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paradigm, we believe that a prolonged titration of insulin administration would produce
similar results, as this would also cause glucose uptake without supplemental energy

Figure 2.7: Insulin is not neuroprotective after moderate CCI TBI. Animals given a
moderate (1.5mm) controlled cortical impact (CCI) injury were injected (i.p.) with either
saline (3hrs post injury) or 10 Units (U) of insulin at either 3, 6, 9 12, 15, or 21hrs after
injury. None of the injection time points showed a significant change in the amount of
tissue spared. (ANOVA, F3,13=0.6, R2=0.15, p>0.05 ± SD; the 3hr and15hr time points
were not included in the statistical analysis due to the high mortality in each group
leaving only an n of 1 in each group. Also, the 21hr time group was excluded from the
statistical analysis as it had only an n of 2. All other groups contained 4 animals). This
lack of neuroprotection may be due to the sequestration of glucose away from the brain
and into adipocytic stores, resulting in energetic failure and neuronal loss.

substrate production through ketosis. Our data suggest that hypoglycemia, independent of
its downstream effects, is not the underlying mechanism of the neuroprotective effect
afforded by fasting.
When monitoring ketone levels after a moderate injury, we found that fasted
injured animals showed a significant increase in the levels of βHB after 24hrs compared
with unfasted injured animals (Table 2.2). However, the level of ketones in fasted injured
animals did not seem to reach the same levels as the fasted naïve animals (although these
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groups could not be directly compared), which may indicate the uptake of ketones in the
injured brain.
To examine the neuroprotective effects of ketones, we subcutaneously implanted
osmotic mini-pumps filled with vehicle (saline), 0.8mmoles D-βHB/kg/day, or
1.6mmoles D-βHB/kg/day immediately after administering a moderate injury, doses
which have been shown to maintain the serum concentration of D-βHB at similar levels
seen with fasting (Tieu et al. 2003). Interestingly, the lower dose of D-βHB significantly
increased cortical tissue sparing compared with vehicle, whereas the higher dose of DβHB did not, indicating that there may be a dosage effect for the efficacy of ketone
administration (Fig.2.8). These data clearly demonstrated that this treatment could have a
beneficial effect on tissue sparing when administered post injury.

Ketones Attenuate Mitochondrial Dysfunction In The Presence Of Calcium
When mitochondria from naïve unfasted animals were incubated with excitotoxic
levels of Ca2+, we found a significant increase in ROS production, as well as increased
NADH levels (Figure 2.9). This would indicate that the calcium is causing mitochondrial
function to become aberrant. Interestingly, when we added ketones (1mM D-βHB and
1mM ACA) to the calcium buffer, ROS levels and NADH levels were significantly
decreased from the calcium buffer levels, and were not significantly different from
control levels (Figure 2.9). Somehow the mitochondria are able to utilize ketones as
substrates to overcome calcium induced dysfunction. When mitochondrial respiratory
capacity through oxygen utilization was measured in the presence of calcium, the
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mitochondria with access to ketones showed significant improvements in state III and
state V respiration rates (Figure 2.10), which are measures of ADP phosphorylation

Figure 2.8: Exogenous ketone administration increases tissue sparing when
administered after moderate (1.5mm) controlled cortical impact (CCI) injury.
β-hydroxybutyrate was administered via subcutaneously implanted osmotic mini-pumps
for 3 days post injury. The lower dose (0.8mMoles/kg/day; n=10) of βHB induced
neuroprotection as measured by increased tissue sparing compared with saline (n=10)
treated animals. There was also a significant difference between the high dose βHB
(1.6mMoles/kg/day; n=6) and the low dose, indicating a dose response to ketone
administration. However, there was no significant difference between vehicle and the
high dose of βHB. (ANOVA, F2, 25=9.0, R2=0.44, p<0.001 SNK; * p<0.001 High βHB vs.
Saline; #p<0.01 High βHB vs. Low βHB ± SD).

capacity and maximum respiratory capacity, respectively. These results are similar to
what we have seen in mitochondria from injured fasted animals compared to uninjured
fasted animals. These data collectively indicate that the presence of ketones is capable of
maintaining mitochondrial function and this may explain how they are able to confer
neuroprotection after injury.
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ROS
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NADH

Figure 2.9: Ketones attenuate Ca2+induced ROS formation and NADH backup.
Exogenous Ca2+ causes changes in mitochondrial bioenergetics in terms of ROS
production and NAD+/NADH cycling. (A) When mitochondria from unfasted naïve
animals are incubated with exogenous Ca2+ (0.5mM), the production of ROS
significantly increases. This is attenuated when ketones (1 mM D-βHB and 1mM ACA)
are added to the buffer, which may be due to their ability to affect the oxidation state of
the Q-cycle within the ETC. (ANOVA, F2, 23=19.420, R2=0.649, p<0.0001 SNK; *
p<.001 compared to Ketones, # p<0.001 compared to Ketones + Calcium, n=8, SD). (B)
Exogenous Ca2+ (0.5mM) also increased NADH when incubated with mitochondria.
Ketone (1mM D-βHB and 1mM ACA) addition significantly decreases these levels,
which indicates that ketones can preserve complex I driven respiration in the presence of
excitotoxicity. (ANOVA, F2, 23=19.41, R2=0.649, p<0.0001 SNK; * p<.001 compared to
Ketones, # p<0.001 compared to Ketones + Calcium, n=8, SD).
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A.

B.

Figure 2.10: Ketones increase mitochondrial function in the presence of exogenous
calcium.
(A) Mitochondria from unfasted naïve animals were isolated and incubated with calcium,
which caused a decrease in mitochondrial function as measured by oxygen consumption.
The addition of ketones (1mM D-βHB and 1mM ACA) significantly increased state III
respiration (t8=3.2) and state Va (t8=3.0) respiration, which are measures of ADP
phosphorylation and maximum ETC function (respectively). Complex II driven
respiration (state Vb) was not significantly different between treatments (t8=2.5),
indicating that calcium mainly affects complex I function. Values are expressed as %
control (mitochondria in buffer without calcium or ketones). Mito + Calcium; n=
5/group, Mito + Ketones and Calcium n=5/group; Unpaired Student‟s t-test, * p<0.05.
(B) Graph shows representative oxygen consumption trace with states and corresponding
substrate additions. Rate is measured in nMoles of oxygen/mg/mL over time. The
presence of calcium causes a flattening of state III respiration as well as state Va, which
is then attenuated by the addition of ketones (1mM D-βHB and 1mM ACA).
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Discussion
Traumatic brain injury occurs in a biphasic manner, beginning with primary
mechanical damage, followed by a more insidious secondary injury cascade. Several
lines of evidence have implicated that mitochondria are key players in the events
constituting secondary injury, which includes increased release of excitatory amino acids
(EAAs), increased lactate and free fatty acid levels (FFA), impaired Ca2+ cycling,
increased ROS production, mitochondrial dysfunction, and induction of cell death
pathways (Faden et al. 1989; Hayes et al. 1992; Sullivan et al. 1998; Sullivan et al. 2000;
Scheff et al. 2004).
Recently there have been growing concerns regarding the timing of nutritional
support for TBI patients and what influence this could have on neurological outcome.
After TBI, there is general unregulated increase in metabolic activity within the first 24
hours after injury, characterized by an increased demand for bioenergetic substrates and
protein catabolism (Caron et al. 1991; Hovda et al. 1992; Hovda et al. 1995; Vespa et al.
2005). Previous clinical reports suggested that "early" dietary intervention may improve
outcome in TBI patients (Pepe et al. 1999; Krakau et al. 2006; Perel et al. 2006),
supporting the general notion that proper nutritional support is vital to sustain increased
metabolic activity. Thus, it may appear counter-intuitive that an acute reduction in overall
caloric intake would be neuroprotective after TBI. However, “early intervention”, as
defined clinically and which has been shown to confer better outcome, is understood to
be 24-72 hours after injury (Krakau et al. 2006; Perel et al. 2006). It is also important to
note that although TBI patients are not getting nutritional support, they are getting intravenous glycolytic compound (e.g. glucose) administration and glucose uptake regulation
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via insulin, which could be shutting down the potentially protective ketogenic pathway
(Robertson et al. 1991; Vespa et al. 2006). In the present study, animals fasted for 48
hours did not show a significant increase in tissue sparing, which may be due to the
exhaustion of metabolic stores, and the collapse of cellular repair mechanisms. Thus, our
experimental results are in accordance with clinical findings, as fasting beyond the initial
24-hour window was not beneficial to outcome.
We have previously shown that TBI induces mitochondrial damage and
dysfunction (Sullivan et al. 1998; Sullivan et al. 2002). The present study clearly
demonstrates that mitochondrial function can be improved by fasting. Specifically,
fasting led to an attenuation of mitochondrial ROS production, oxidative damage, and
enhanced Ca2+ buffering. Isolated mitochondria from fasted and injured animals also
showed enhanced utilization of ADP, indicative of efficient ATP production. Moreover,
our behavioral data indicated that the cognitive abilities of fasted injured animals were
not significantly altered as compared to sham animals, highlighting the potential safety of
appropriately timed fasting following TBI.
However, fasting induces many evolving biochemical changes at a systemic level,
including ketogenesis, lipogenesis, and hypoglycemia (Burge et al. 1993; Pan et al.
2000). During extended fasting (more than 9-12 hours), decreasing insulin levels initiate
the mobilization of stored energy deposits contained in hepatic and adipose tissues
(Fromenty et al. 2004). Once glucose levels are depleted, the body shifts to the oxidation
of fatty acids to maintain ATP levels. This results in increased hepatic synthesis of ketone
bodies (principally, βHB and acetoacetic acid), and the release of free fatty acids (FFA)
from the breakdown of triacylglycerols and their mobilization from adipose stores
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(Fromenty et al. 2004; Nehlig 2004). Ideally, identification of the key mediator(s) of
fasting-induced neuroprotection might allow us to obviate systemic complications
associated with fasting and ensure a more uniform effect. As such, to ascertain potential
underlying mechanism(s), we used a reductionist approach to independently target two
well-known physiological adaptations resulting from fasting, namely, hypoglycemia and
ketosis.
Hypoglycemia is an early response to fasting, and we have seen its induction
within the first 9 hours. However, in our effort to mimic this condition with acute insulin
administration in the absence of calorie restriction, we failed to see a neuroprotective
effect after moderate TBI at any injection time-point examined in our study. Moreover,
we found that acute hypoglycemia proved fatal in some treatment groups, which may
have important clinical implications; however, we recognize that insulin boluses are not
administered to TBI patients with normal glycemic levels. Our experimental paradigm
involved abrupt increases in insulin levels, which may have caused glucose sequestration
through enhanced selective insulin-sensitive glucose transporter activity, which is not
present on neurons (El Messari et al. 1998; Alquier et al. 2001). As a result, there would
be a deficiency in both glucose and alternative energy substrates (i.e., ketone bodies) to
provide sufficient fuel for damaged neurons to facilitate repair mechanisms, which may
account for the lack of protection seen with insulin administration after TBI. In the
present study, we did not examine whether a more gradual elevation of blood insulin
levels might yield a neuroprotective effect. However, we do not believe that sustained
hypoglycemia through insulin administration would be protective due to observations in
clinical patients that sustained insulin administration indicated poorer outcome after
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injury (Vespa et al. 2006). Also, supporting our findings are previous reports that acute
glucose administration (which also induces spikes in insulin levels) post injury decreases
neuroprotection in both human and animal studies (Robertson et al. 1991; Cherian et al.
1998). However, we could have included an injured fasted group that was administered
insulin after injury as a way to mimic the clinical treatment of a TBI patient, and as such
is an acknowledged limitation of our current studies.
Given that acute insulin-induced hypoglycemia did not explain the
neuroprotective effect of fasting against moderate TBI, we next examined whether
compounds classically referred to as ketone bodies (i.e., D-βHB) could be underlying the
neuroprotective effect of fasting. Ketone bodies, which are preferentially utilized by the
brain after TBI, have been shown to increase cortical levels of ATP after injury and
improve mitochondrial function, possibly through similar mechanisms (Prins et al. 2004).
This upregulation of ketones occurs shortly after hypoglycemia has been induced, within
15hrs (data not shown) due to lack of caloric intake. Infusion of the principal ketone
body, D-βHB, alone replicated our findings with a 24-hour fast after TBI in terms of
tissue sparing. Interestingly, only the lower dose of D-βHB was neuroprotective after
moderate injury, suggesting a preliminary dose-response relationship.
The neuroprotective activity of ketone bodies has been demonstrated in various
models of neurological injury and disease, both in vivo and in vitro (Yager et al. 1992;
Kashiwaya et al. 2000; Massieu et al. 2003; Tieu et al. 2003; Smith et al. 2005; Yamada
et al. 2005; Noh et al. 2006; Bough et al. 2007; Maalouf et al. 2007). We have also
previously demonstrated that ketone bodies attenuate ROS formation in isolated
mitochondria exposed to oligomycin, the maximum ROS producing inhibitor of complex
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V (ATP synthase) (Kim et al. 2007). As a part of its metabolic utilization, D-βHB is
converted to acetoacetate (ACA) by β-hydroxybutyrate dehydrogenase, thereby reducing
NAD+ to NADH+H+ (Dardzinski et al. 2000; Rho et al. 2002; Nehlig 2004). This limits
the available pool of NAD+ and alters the redox potential of ubiquinone (Co-enzyme Q10)
from a reduced to an oxidized state, and hence diminishes the number of electrons
available to spin off and form superoxide (O2.-) radicals (Nicholls et al. 2002; Nehlig
2004). In addition, the conversion of D-βHB to acetyl-CoA produces endogenous
succinate, a complex II (succinate dehydrogenase) substrate independently of the TCA
cycle; and acetyl-Co also enters the TCA cycle producing additional complex II
substrates (McKee et al. 2003). Thus, administration of ketone bodies may yield two
independent sources of substrates for Complex II, which coupled with the alteration of
the redox state of ubiquinone, ultimately helps to reduce ROS and maintain normal
mitochondrial function.
It is well known that TBI results in excessive influx of Ca2+ into the cell, resulting
in increased Ca2+ loading and mitochondrial stress, and eventual dysfunction (Nicholls et
al. 2003; Brookes et al. 2004; Gunter et al. 2004; Sullivan et al. 2004). In our studies we
have shown co-incubation of isolated mitochondria with ketone bodies in the presence of
excitotoxic levels of Ca2+ resulted in increased ADP utilization (state III) and maximum
electron transport chain function (state V) (Figure 2.10), both indicative of an overall
improvement in mitochondrial function. These data showing functional recovery are
similar to our results from mitochondria from fasted injured animals. Together with our
data showing that ketone bodies also decrease ROS production and increase the
efficiency of NADH utilization in the presence of exogenous Ca2+ (Figure2.9), it suggests
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that ketones increase the ability of the cell to withstand excitotoxic injury by glutamate
mediated Ca2+ influx after traumatic injury. Our current data indicates that ketones could
be working to maintain mitochondrial homeostasis through ETC maintenance as well as
cellular Ca2+ regulation.
Studies investigating the metabolic fate of glucose after TBI have shown post
injury glucose utilization shifting from energy production to cellular repair mechanisms
via the pentose phosphate pathway. Therefore, the addition of exogenous ketone bodies
may ameliorate systemic complications resulting from TBI, by allowing pyruvate and
glucose to be utilized for support and repair mechanisms in other tissues while providing
metabolic support for neuronal function (Bartnik et al. 2005; Bartnik et al. 2007; Dusick
et al. 2007). Additionally, monocarboxylate transporters (the major ketone transporters)
have been shown to be upregulated by TBI as well as the ketogenic diet; which would
indicate that ketones can be effectively taken up and utilized preferentially after injury in
our experimental paradigm (Morris 2005; Prins et al. 2006; Prins 2008). Indeed the
uptake of ketones by these transporters seems to be substrate concentration dependent
manner, thereby allowing for rapid uptake in the event of increased ketone availability
(Prins 2008). Interestingly, there are also studies indicating that the human brain
possesses a greater capacity for ketone utilization compared to the rodent brain, which
may indicate that ketone administration may have greater neuroprotective effects in
clinical TBI patients (Prins 2008). Together, the utilization of these endogenous repair
systems, along with energetic substrate supplementation, could account for the protection
seen with ketone body administration post injury. These previous studies, along with our
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current data demonstrate strong support for a protective role for ketone bodies in the
phenomenon of fasting-induced neuroprotection following moderate TBI.
Although significant, the neuroprotective effect seen with ketone administration
was not as robust as that seen with fasting after injury. It is possible that coadministration of ACA along with D-βHB could prove more efficacious due to dual
insertion sites in the metabolic system. Although, in human subjects there was a 13 fold
increase in cerebral uptake of βHB after 3.5 days of fasting, whereas there was not
increase in uptake of ACA (Hasselbalch et al. 1995). Also, other systems upregulated by
the complex network of fasting may also be contributing to the neuroprotective effect
seen with fasting post injury. Regardless of other possible neuroprotective mechanisms,
our studies have shown that ketones play an integral role in the attenuation of tissue loss
and mitochondrial dysfunction in the mechanism of fasting induced neuroprotection.
Hypoxia inducible factor- α (HIF-1α) is responsible for the upregulation of
glycolytic enzymes, glucose transporters, angiogenesis genes, and monocarboxylate
transporters (MCT), which are responsible for ketone uptake into the brain (Zhang et al.
2005). Its expression is upregulated during times of decreased oxygen levels, therefore
HIF-1α expression could be transiently increased in a hypoxic region of the injury site
(Acker et al. 2004; Prins 2008); however the duration of hypoxia may not be sufficient to
preserve cellular function. Indeed, the upregulation of a key enzyme of the (PPP) pentose
phosphate pathway (glucose-6-phosphate dehydrogenase (G6PD)) is less sensitive to
HIF-1 mediated induction and as such has a slower induction rate (Gao et al. 2004). This
transient ischemia may prevent the upregulation of G6PD and inhibit the supplementation
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of the damaged endogenous antioxidant glutathione system after TBI (Ansari et al. 2008;
Ansari et al. 2008).
Although HIF-1α expression has not been directly measured after fasting, it has
been measured after ketogenic diet administration and direct intra-ventricular ketone
infusion (Puchowicz et al. 2008). Interestingly, ketotic animals show an upregulation in
the expression of HIF1α, and this upregulation can be achieved via diet or direct infusion
of βHB into the brain (Puchowicz et al. 2008). Also, these animals have increased
expression of Bcl-2 proteins, which could indicate that ketones are involved in promoting
an anti-apoptotic mechanism (Puchowicz et al. 2008). It is postulated that the increased
production of succinate via ketone utilization may be responsible for HIF1α stabilization
as it can directly inhibit HIF1α- prolyl-dydroxylases, the protein responsible for HIF1α
breakdown (Schofield et al. 2004; Puchowicz et al. 2008). Indeed, strategies that either
provide additional succinate (propionate) or cause the inhibition of complex II by 3NP
(3-nitropropionic acid), and therefore the increase of succinate, induce the stabilization of
HIF-1α (Goldberg et al. 1966; Koivunen et al. 2007). Moreover, brain tissue of ketotic
animals, be it from dietary supplementation or infusion of ketones, contains significantly
higher succinate concentration (Goldberg et al. 1966; Puchowicz et al. 2008). As ketones
are able to increase the pool of available succinate, this could also contribute to the
upregulation of beneficial enzymes as well as the increased uptake of ketones for
mitochondrial utilization. This also could explain why MCT upregulation coincides with
ketone availability (Prins et al. 2004). It should be noted that ketones can also be utilized
more readily than glucose by the cell to create proteins and lipids (cholesterol in myelin),
which could further enhance the ability of the cell to repair itself (Morris 2005).

63

Furthermore, as glycolytic products are in a state of enzymatic equilibrium (McKee et al.
2003), the preferential uptake of ketones over pyruvate into the mitochondria could shift
glycolytic intermediates toward utilization by the pentose phosphate pathway, which
increases NADPH levels thereby supporting the endogenous glutathione system. Ketones
would therefore increase mitochondrial substrate production, mitochondrial function, and
increase HIF-1 mediated upregulation of proteins/transporters that could enhance cellular
repair mechanisms and ketone uptake/distribution (Figure 2.11). It is also important to
mention that HIF-1 is also responsible for the upregulation of pro-apoptotic proteins,
however it has been suggested that these proteins are upregulated with prolonged HIF-1
activation (Acker et al. 2004), which could explain why our high dose of ketone
administration did not show as robust neuroprotection as fasting and why a 48hr fast did
not increase tissue sparing. This indicates that investigation into duration of treatment is
needed in order to determine the maximum effectiveness of ketone administration.
In summary, we have shown that fasting after moderate TBI exerts a significant
neuroprotective and positive cognitive effect compared with unfasted injured animals. In
attempting to elucidate the underlying mechanism(s) of fasting-induced neuroprotection,
we found that acute administration of insulin alone, which mimics fasting-induced
hypoglycemia, was not neuroprotective and, in fact, was fatal in some treatment groups.
More importantly, we demonstrated that exogenous ketone body administration in the
absence of fasting resulted in neuroprotection after moderate injury as measured by
cortical tissue sparing. Similar to observations seen in mitochondria from animals fasted
post injury, studies using mitochondria in an excitotoxic damage model suggest that the
beneficial actions of ketone bodies likely stem from their ability to enhance
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Figure 2.11 Hypothesis of how ketones and HIF-1 work together to preserve
mitochondrial function.
1) Ketones (βHB and ACA) are utilized by mitochondria to produce Krebs cycle
intermediates, which produce substrates for the ETC (NADH and FADH2). This allows
the mitochondria to produce sufficient energy, in the form of ATP, to maintain
homeostasis. 2) The conversion of ketones into acetyl-CoA also produces succinate,
which can be utilized by the Krebs cycle to produce energy. 3) However, succinate has
also been shown to block HIF-1α prolyl-hydroxylases, which in turn stabilizes the levels
of HIF-1α. This allows HIF-1α to dimerize with HIF-1β and travel to the nucleus, where
it is responsible for the upregulation of proteins involved in angiogenesis, glucose uptake,
glycolysis, and ketone uptake. 4) It is through the HIF-1 mediated upregulation of MCTs
that we believed it is possible for increased ketone levels to increase their uptake into the
cell for utilization as energetic substrates, as well as building blocks for (5) protein and
lipid synthesis. 6) Oxygen is responsible for the activation of HIF-1α prolylhydroxylases, which alter HIF-1α, which allows the von Hipple-Lindau protein to target
it for proteasome mediated degradation. ROS can also inhibit HIF-1α prolylhydroxylases, which may explain how HIF-1α expression is upregulated by injury.
Ketone metabolism is more efficient than glycolysis in terms of enzymatic steps and ATP
requirements. 7) Glycolysis requires 11 enzymatic steps, whereas ketone metabolism
only requires 3 steps. However, because HIF-1 upregulates glycolytic enzymes the
utilization of ketones by mitochondria could be shifting glycolytic intermediates into the
(8) pentose pathways, which is responsible for the increase of NADPH levels and in turn
support of the endogenous glutathione system.
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mitochondrial function and reduce ROS production.
As the current management of adult patients with severe TBI generally includes
fasting (i.e. use of i.v. normal saline without dextrose) for about 48 hours, our findings in
this animal model support this approach, assuming appropriate monitoring for
hypoglycemia. Our results also suggest the need for further exploration into the
administration of alternative fuels at bench and bedside, and as such have begun to lay a
preliminary mechanistic basis for the investigation of novel therapeutic interventions.

Copyright © Laurie M. Davis 2008
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Chapter 3
UCP Mediated Free Fatty Acid Uncoupling of Isolated Cortical Mitochondria from
Fasted Animals; Correlations to Dietary Metabolic Modulations

Introduction
Mitochondrial respiration is responsible for generating the majority of ATP used
in normal cellular functions. This energy is produced by the electron transport chain
(ETC), which translocates protons from the matrix to the intermembrane space, thereby
creating a charge potential across the inner membrane (ΔΨ). Protons enter the F1 subunit
of ATPsynthase (Complex V), causing it to rotate, which then causes a conformational
change in the Fo subunit thereby catalyzing the phosphorylation of ADP to ATP (Boyer
1997; Boyer 1999; Boyer 2000; Nicholls et al. 2000; Nicholls et al. 2002). These protons
can only facilitate ATP production if the concentration of protons is higher within the
intermembrane space than the matrix; and in fact the ATPsynthase can hydrolyze ATP if
ΔΨ reaches low levels in an attempt to recapitulate ΔΨ (Sullivan et al. 2000). This
process is the basis for oxidative phosphorylation or “cellular respiration”, due to the
resultant consumption of oxygen as the final electron acceptor (Nicholls et al. 2000;
Nicholls et al. 2002). The maintenance of this system is critical to cellular survival, and
its dysfunction ultimately leads to the initiation of cell death pathways
(apoptosis/necrosis) (Sullivan et al. 2005).
The dysfunction of mitochondrial systems has been associated with many injury
and disorder models, and has been described as the key cell death determinant in the
recovery or loss of cellular integrity (Verweij et al. 1997; Xiong et al. 1997; Sullivan et
al. 1998; Xiong et al. 1998; Cock et al. 2002; Sullivan et al. 2003; Tieu et al. 2003;
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Brookes et al. 2004; Lifshitz et al. 2004; Patel 2004; Sullivan et al. 2005; Xiong et al.
2005). It has also been suggested that the preservation of mitochondrial function would
thereby increase the ability of the cell to repair damage caused by these insults (Scheff et
al. 1999; Sullivan et al. 1999; Lifshitz et al. 2004; Pandya et al. 2007). The perpetrators
of a great deal of this damage are the highly volatile reactive oxygen species (ROS) and
reactive nitrogen species (RNS), which can oxidize proteins, lipids, and DNA (Nicholls
et al. 2000; Brookes et al. 2004; Hall et al. 2004; Singh et al. 2006; Singh et al. 2007).
These ROS/RNS are caused by increased electron back up within the ETC, which
prolongs the reduction time of ETC intermediates thereby increasing the probability of
electron escape and combination with oxygen or nitrogen.
Specific proteins within the mitochondrial inner membrane have recently been
implicated in an endogenously regulated anti-ROS system, thought to function primarily
to protect the brain from oxidative stress (Garlid et al. 1998; Klingenberg 1999; Richard
et al. 2001; Echtay et al. 2002; Echtay et al. 2003; Mattiasson et al. 2003). These
uncoupling proteins (UCPs) function to uncouple proton translocation from the
phosphorylation of ADP; and in doing so alleviating the electron congestion within the
electron transport chain (Negre-Salvayre et al. 1997; Echtay et al. 2002; Echtay et al.
2003; Sullivan et al. 2003). UCPs are upregulated through the peroxisome proliferator
activating receptor (PPAR) pathway in response to shifts in metabolic substrate
utilization. PPARs are members of the hormone receptor super family and are mainly
involved in the regulation of lipid metabolism. (Staels et al. 1997; Pineda Torra et al.
1999; Debril et al. 2001; Kiec-Wilk et al. 2005). UCPs can be actively involved in lipid
breakdown in both liver and adipocytes and their expression is upregulated by fasting,
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possibly through the formation of free fatty acids via beta oxidation (Sullivan et al. 2003).
UCPs are also believed to be activated by certain naturally occurring FFA derivatives; as
well as endogenously synthesized free fatty acids (FFA), which are simultaneously
released as a byproduct of triglycerides breakdown in adipocytes (Debril et al. 2001; Li et
al. 2002; Grav et al. 2003; Sullivan et al. 2004; Shi et al. 2005).
The high fat/low carbohydrate ketogenic diet (KD) was originally developed as an
attempt to mimic the physiological effects of fasting by inducing the production of ketone
bodies, which have been suggested to be the neuroprotective mechanism of both fasting
and KD (Bailey et al. 2005; Davis et al. 2008). However, during the production of
ketones, free fatty acids are also produced as a byproduct of triglyceride breakdown.
UCPs have been shown to be upregulated in response to ketogenic diet administration
and could be involved in the efficacy of this dietary modulation, although it is not fully
understood which FFAs are responsible for activation (Sullivan et al. 2004). Therefore,
the purpose of our study was to investigate fasting induced modulation of FFA, as well as
the ability of a variety of different FFA to uncouple oxidative phosphorylation and reduce
ROS production in isolated cortical mitochondria with upregulated UCPs. Here we are
using FFAs ranging from 4-22 carbons in length with varying levels of saturation. The
results of our study should give us some insight into how diet modulates the metabolic
breakdown of lipids and what influence this has on mitochondrial function.
The results from this study have shown that UCP2 expression can be upregulated
by fasting in both naïve and injured animals. We have also investigated the ability of
FFAs of various chain lengths to activate UCP mediated uncoupling and ROS
production. As UCPs and their activation seem to be an integral part of fasting induced
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neuroprotection we also have shown the upregulation of FFAs after fasting in serum and
brain tissue. Collectively, our work has attempted to shed light on the role of specific
FFAs within the UCP mediated uncoupling mechanism, as a potential target for
therapeutic supplementation after injury.

Methods
Animals
All experiments were conducted using adult male Sprague-Dawley rats, which
were housed 3 per cage in a facility which maintained a 12-hour light/12-hour dark cycle.
All experimental animal procedures were approved by the University of Kentucky
Animal Care and Use Committee. All animals used for mitochondrial isolation were fed a
balanced diet ad libitum until 24hrs before mitochondrial isolation at which time they
were fasted for 24hrs.

Mitochondrial Isolation
Cortical mitochondria were isolated from rats by differential centrifugation
techniques as described previously in chapter 2. Prior to isolation naïve animals were
fasted for 24 hrs in order to upregulate UCPs for FFA screen.

Western Blotting
For these studies a selective antibody for UCP2 (Everest Biotech, Oxfordshire,
UK) was utilized to determine expression levels in isolated cortical mitochondria from
fasted naïve, unfasted naïve, unfasted injured, and fasted injured animals. A protein assay
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kit was used prior to loading (Pierce Rockford IL 61105), and samples were prepared as
previously stated (Sullivan et al. 2004). The blots were incubated with primary goat antiUCP2 and mouse anti-VDAC antibodies diluted 1:1000 and 1:10,000 respectively. Antigoat (800nM) and conjugated goat anti- mouse IgG (700nM) (Rockland
Immunochemicals Inc, Gilbertsville, PA) antibody were used at 1:25,000 and 1:10,000
respectively. Blots were subsequently imaged on a LiCore Odyssey imaging machine.
Fluorescence values for UCP2 expression were divided by the corresponding VDAC
values to control for protein concentration variability. Values are expressed as
UCP2/VDAC in arbitrary units (AU).

Mitochondrial Respiration
After performing a BSA protein assay, a 30ug sample of mitochondria was placed
in 250μL of KCL respiration buffer (125mM KCl, 2mM MgCl, 2.5mM KH2PO4, 20mM
HEPES ) inside a constantly stirred thermo-regulated sealed Oxytherm chamber. Oxygen
within the chamber was measured using a Clark-type oxygen electrode. Oxygen
consumption in response to the addition of substrates was measured in order to determine
functionality of the mitochondria, along with the ability of the different FFA to uncouple
this respiration from ATP production. Pyruvate (5mM) and Malate (2.5mM) were added
in order to prime the Krebs cycle and build membrane potential. ADP (150µM) was
added to assess oxidative phosphorylation capacity, which is an indication of the health
of the electron transport chain. The mitochondria were then locked into state IV
respiration by addition of oligomycin, an ATP synthase inhibitor; to create a baseline rate
of oxygen consumption due to inner membrane leakage so that any increase in oxygen
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consumption would be the result of uncoupling via FFA. Final concentrations of 60µM of
FFAs of varying chain length were added after oligomycin during separate runs to
activate UCPs. BSA (.6%) was added to sequester the exogenous FFAs to bring
respiration back to baseline, and to assess any damage that the FFA may have caused to
the mitochondrial ETC. “Good UCP activators” were characterized by FFAs that were
able to both significantly increase respiration upon their addition and when sequestered
the rate of respiration returned to baseline. For statistical purposes the increase in rate as a
result of the addition of FFA as well as the rate resulting from the addition of BSA were
expressed as % of the rate resulting from the addition of oligomycin (% of state IV).
These rates were compared to each other using a student‟s t-test.

ROS Assay
Isolated cortical mitochondria from fasted animals were used to asses the ability
of FFAs to attenuate ROS production in the presence of an electron transport chain
complex inhibitor (Oligomycin). DCF (2, 7-dihydrodichlorofluorescein 10µM) and HRP
(Horse Radish Peroxidase 10µM) were used as indicators of ROS production. A
concentration of 60µM was used for each FFA in 50µL of KCl respiration buffer
containing Pyruvate and Malate. Half of the samples were co-incubated with oligomycin
so that the reduction of ROS would be correlated to the activation of UCPs instead of the
activity of complex V. These samples were compared to their respective control samples,
either with or without FFA, and expressed as % increase in ROS of control.
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Gas Chromatography/Mass Spectrophotometry
Samples were taken from a separate cohort of animals that were either fasted or
fed ad libitum for 24 hrs. Serum samples were taken at both 0hrs and 24 hrs, whereas
CSF and Brain tissue were collected at 24hrs only. FFAs from serum samples and CSF
were brought to an approximate pH of 2 with HCl. The samples were supplemented with
Linoleic acid D4, Arachidonic Acid (AA) D8, and Docosahexaenoic acid (DHA)-D5. Ethyl
Acetate was then added as an extraction medium. The sample was vortexed for ~30
seconds and centrifuged at 2,000 rpm for 10 minutes. The organic layer was then
removed and poured over Sodium Sulfate (NaSO4), to remove residual water. This Ethyl
Acetate extraction was then repeated and the organic layer was again poured over NaSO4.
The organic layers from each extraction step were then combined and the samples were
evaporated under N2 at 37°C. Samples were then reactive with 10% pentaflourobenzyl
bromide (PFBB) and 10% di-isopropylethylamide (DIPE) for 20 minutes at 37°C. After
the samples were brought to room temperature they were evaporated under N2 at 37°C.
Undecane was added to dissolve the extracts for injection on to the GC/MS. See figure
3.1 for an example GC/MS chromatogram.
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Figure 3.1 Serum GC/MS chromatograms from a Fasted and Control animals
This figure shows a representative trace for the serum GC/MS FFA content of Fasted and
Control animals. A) Control baseline trace (0hr) B) Fasted baseline trace (0hr) C) Control
24hr trace D) Fasted 24hr trace. A and B were cut into 2 panels for ease of viewing.

Brain samples (~100mg) were homogenized in 10mL of cold Folch solution
(CHCl3:CH3OH, 2:1 ratio), and brought to ~pH 2. Nitrogen was introduced and samples
were uncubated for 30 minutes at room temperature. 4mLs of Normal Saline (0.9%) was
added and samples were centrifuged at 2,000 rpm for 10 minutes. The organic layer was
taken off and poured poured over Sodium Sulfate (NaSO4), to remove residual water.
This layer was then supplemented with Linoleic acid D4, Arachidonic Acid (AA) D8, and
Docosahexaenoic acid (DHA)-D5, and subsequently evaporated under N2 at 37°C. The
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ethylacetate extraction procedure was then followed as previously stated. Undecane was
added to dissolve the extracts for injection on to the GC/MS.

Statistical Analysis
For respiration studies independent t-tests were used to determine the significance
between FFA and BSA addition. ROS and Western blot studies used a One-way ANOVA
with a student-newman-keuls post hoc when appropriate. GC/MS studies used paired
(serum) and unpaired t-tests (brain and CSF) when appropriate. Significance was set at
p<0.05.

Results
Uncoupling Protein 2 Expression
Our representative western blot shows that fasting increases the expression of
UCP2, which is in accordance with stated literature that these proteins are upregulated in
a fasted state (Li et al. 2002; Grav et al. 2003; Sullivan et al. 2004). Injury alone did not
induce a significant increase UCP2 expression; however, injured fasted animals did show
significantly increased mitochondrial UCP2 expression (Figure 3.2). Interestingly both
injury groups were significantly decreased from fasted naïve levels, indicating that UCP2
expression is down regulated in response to injury. Injured control expression was not
significantly different from either fasted injured or naïve control levels (Figure 3.2). This
implies that fasting induces upregulation and activation of the UCP system, which would
further implicate it in the neuroprotective mechanism of fasting. Additionally, this
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B.
~32kDa
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Figure 3.2 Mitochondrial UCP2 expression is modulated after fasting and injury.
A) Fasted animals showed significantly increased UCP2 protein expression levels
compared to injured fasted, injured control, and naïve control animals. Naïve control
animals showed significantly decreased UCP2 expression compared to both naïve and
injured fasted animals. Injured control expression was not significantly different from
injured fasted or naïve control levels. The UCP2 fluorescence level of each sample was
divided by its corresponding VDAC fluorescence level as an internal control for protein
concentration. Expression levels are expressed as arbitrary units (AU). (Injured Control
n=3, Injured Fast n=5, Naïve Control n=4, Naïve Fast n=5) ANOVA p<0.05 F3, 16=8.5,
R2=0.66, SNK *p<0.05 ***p<0.001. B) Representative western blot, each band is at
32kDa. A= Injured Control, B= Injured Fasted, C= Naïve Control, D= Naïve Fasted.
indicates that we can use a fasting paradigm to up regulate UCP2 as a means to study the
effects of FFA administration on mitochondrial respiration and ROS production.
Free Fatty Acid UCP Activation
It has been shown that both ROS and FFAs must be present in order to activate
UCPs and that the duration of this activation is dependent upon the level of each of these
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factors (Echtay et al. 2001; Echtay et al. 2002; Echtay et al. 2003). It is also known that
the addition of oligomycin to isolated mitochondria causes increased ROS production due
to maximization of membrane potential via the blockage of complex V (ATPsynthase)
(Sullivan et al. 2003). Based upon this information, we used a 24hr fasting paradigm to
upregulate UCPs in order to screen FFAs of different chain lengths and saturation states
to determine their effect on uncoupling induction (Table 3.1 and Figure 3.3).

FFA

Carbons

Butyric
Capronic
Octanoic
Valproic
Decanoic
9-Decanoic
Lauric
Cis-5-Doecenoic
Myristic
Myristoleic
Pentadecanoic
Palmitic
Palmitoleic
Heptadecanoic
Cis-10-Heptadecanoic
Linoleic
Oleic
Stearic
Arachidonic
Eicosapentaenoic
Docosahexaenoic

4
6
8
8
10
10
12
12
14
14
15
16
16
17
17
18
18
18
20
20
22

Dbl
Bonds
0
0
0
0
0
1
0
1
0
1
0
0
1
0
1
2
1
0
4
5
6

Table 3.1 Names and chain length of FFAs screened.
This table depicts the chain length and saturation state of each of the FFAs we screened
for their ability to induce UCP mediated activation of respiration and ROS reduction.
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Figure 3.3 Structures of individual FFAs screened.
This figure depicts the individual structures of all FFAs tested in our studies. Pictures
were created using ADC/ChemSketch Freeware, Advanced Chemistry Development, Inc.
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Our results show that chain length is not an indicative factor in determining the ability of
a FFA to activate UCPs, nor is saturation, within the scope of this study (Figure 3.4). In
fact, we found FFAs that uncoupled mitochondria throughout the chain length spectrum.
Palmitoleic (C16), Myristic (C14) and Butyric (C4) acid were all able to uncouple
mitochondria effectively upon addition and with BSA addition returned to state IV levels;
thereby indicating minimal damage to the inner membrane (Figure 3.4). DHA, EPA and
AA also exhibited similar behavior upon addition to isolated mitochondria from fasted
animals (Figure 3.4). Although many of the other FFAs we tested were able to increase

Figure 3.4: Free fatty acids activate UCP mediated uncoupling of mitochondria.
Here we show the ability of various FFA to activate uncoupling in mitochondria isolated
from fasted animals. Each FFA “change over state IV” was compared via t-test to its
respective “recovery to state IV” rate. When we screened fatty acids for their ability to
activate UCP mediated uncoupling we found no correlation between chain
length/saturation and increased respiration. Butyric (t6=2.5), Myristic (t8=5.2),
Palmitoleic (t4=8.4), Heptadecanoic (t6=3.0), Oleic (t4=10.0), Stearic (t6=1.5),
Arachidonic (t4=5.2), Eicosapentaenoic (t4=6.8), and Docosahexaenoic (t4=5.1) acids
showed significant differences between the increase from state IV rate upon their addition
and the recovery to state IV rate upon addition of BSA. This indicates that they are not
damaging the membrane or membrane bound proteins of the ETC. *p<0.05 SD.
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oxygen consumption after addition, BSA addition was not able to bring the rate of
respiration back to basal state IV levels, which means that they were not “good UCP
activators” and may have been damaging the inner or outer membrane and/or membrane
bound proteins that comprise the ETC. Others showed a significant difference between
FFA rate and BSA rate, however, the increase in rate was not increased above 100% of
state IV, and thus we cannot call them “good UCP activators”. Interestingly, Valproic
acid, which has been implicated as a protective agent in seizure models, did not exhibit
an ability to significantly uncouple mitochondria when compared to its BSA rate (Figure
3.4). This seems to indicate that Valproic acid is involved in an alternative mechanism of
seizure attenuation. Although oleic (C18), Heptadecanoic (C17), and Stearic (C18) acid
also showed marginal increases above 100% of state IV, but significant differences
between FFA and BSA respiration rates, they could, in fact, be contributing to UCP
mediated ROS reduction (Figure 3.4).

Free Fatty Acid Attenuation of Reactive Oxygen Species
In order to study the ability of FFAs to reduce ROS production we have utilized
oligomycin due to its ability to maximize ROS production in isolated mitochondria,
thereby allowing us to attribute the reduction of ROS production to the activation of
UCPs. We co-incubated FFAs and isolated cortical mitochondria from fasted animals to
determine their ability to attenuate ROS via UCP activation in the presence of a complex
V inhibitor (Oligomycin). The FFAs selected for this either had been classically shown to
be reducers of ROS or were shown to function as “good UCP activators”.
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In correlation with our respiration studies in which Valproic acid failed to
increase the respiration rate above state IV, it also failed decrease to ROS production in
the presence of oligomycin (Figure 3.5). Similarly, Cis-10-heptadecenoic, linoleic,
heptadecanoic, palmitic, and stearic acid were also unable to attenuate ROS production
(Figure 3.5). All of these FFA did show some modulation of mitochondrial respiration,
however they were either not “good UCP activators” or did not increase respiration above
state IV, all of which would indicate that they would not be able to attenuate ROS
production through activation of UCPs thereby validating our assay. Although
myristoleic acid was a robust activator of UCP mediated uncoupling and showed a 50%
decrease in ROS production, due to high variability this level was not a significant
decrease (Figure 3.5).
DHA, EPA, AA, Oleic, Myristic, Butyric, and Palmitoleic acid all showed
significant decreases in ROS production, which is in agreement with their respective
respiration studies(Figure 3.5). Interestingly, Oleic acid only increased respiration to a
small degree, which suggests that its ability to attenuate ROS production could either be
through a limited activation of UCPs or an alternative mechanism.
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Figure 3.5 Free fatty acids attenuate ROS production in isolated mitochondria
Here we tested FFA from our respiration studies which were either “good activators of
UCPs” or have been classically associated with antioxidant properties. Our results show
that Myristic, Oleic, Butyric, and Palmitoleic significantly reduced ROS production. Of
these, all significantly increased respiration, however Oleic did not seem to increase
respiration very far above 100%. Myristoleic also reduced ROS production by 50%,
however was not significant. ANOVA SNK A) F3, 15=41 R2=0.91; B) F2, 8=11 R2= 0.78;
C) F3, 11= 1.2 R2= 0.30; D) F3, 15= 6.3 R2= 0.61; E) F3, 11= 8.0 R2= 0.75; *p<0.05 SD.
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Fasting Induced Changes in Free Fatty Acid Levels in Vivo
It is known that fasting induces a metabolic shift to the upregulation of FFAs,
which are used for various cellular functions. As our previous data has shown, they play a
role in UCP activation and subsequent UCP mediated ROS reduction. In the
aforementioned studies we used a broad range of FFAs, in terms of chain length and
saturation. Unfortunately it is not known which FFAs are increased during fasting, so it is
difficult to correlate our in vitro mitochondrial studies as a possible mechanism of fasting
induced neuroprotection. Therefore, we measured the upregulation of five of our most
probable FFAs (Linoleic, Oleic, Arachidonic, Eicosapentaenoic, and Docosahexaenoic)
from our respiration and ROS studies to probe for in serum, brain tissue, and CSF of
adult male Sprague Dawley rats.

Serum
In order to determine the levels of FFAs in serum we used both a control and
fasted group, which included both a baseline serum sample and 24hr serum sample. Each
of the groups 24hr samples, which are expressed as % of control level (baseline), were
compared to their respective baselines using a paired t-test. This would allow for an
accurate measure of increases within each animal as a result of dietary modulation.
Control animals, those not fasted for 24hrs, did not show an increase in any of the
measured FFA, indicating that any increase in these FFAs would be due to the
implementation of fasting (Figures 3.6-3.10).
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Figure 3.6 The effect of fasting on serum levels of Linoleic acid.
Animals fasted for 24 hrs showed a significantly increased level of serum Linoleic acid
compared with 0hr baseline levels (t4=4.5). There was no change in the levels of Linoleic
acid in serum from unfasted control animals (t3=1.1). Paired Student‟s t-test **p<0.01,
n=4 (Control), 5 (Fasted) SD.

Figure 3.7 The effect of fasting on serum levels of Oleic acid.
Animals fasted for 24 hrs showed a significantly increased level of Oleic acid in serum
compared with 0hr baseline levels (t4=4.0). There was no change in the levels of Oleic
acid in serum from unfasted control animals (t4=1.9). Paired Student‟s t-test *p<0.05, n=5
SD.

85

Figure 3.8 The effect of fasting on serum levels of Arachidonic acid.
Animals fasted for 24 hrs showed a significantly increased level of serum Arachidonic
acid compared with 0hr baseline levels (t4=2.9). There was no change in the levels of
Arachidonic acid in serum from unfasted control animals (t4=0.95). Paired Student‟s ttest *p<0.05, n=5 SD.

Figure 3.9: The effect of fasting on serum levels of Eicosapentaenoic acid.
Animals fasted for 24 hrs showed a trend toward an increased level of Eicosapentaenoic
acid in serum compared with 0hr baseline levels (t3=3.1). There was no change in the
levels of Eicosapentaenoic acid in serum from unfasted control animals (t4=0.305). Paired
Student‟s t-test *p<0.05, n=4 (Fasted), 5 (Control) n=5 SD.
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Figure 3.10 The effect of fasting on serum levels of Docosahexaenoic acid.
Animals fasted for 24 hrs showed a trend (p=.0974) toward an increased level of
Docosahexaenoic acid in serum compared with 0hr baseline levels (t4=2.2). There was no
change in the levels of Eicosapentaenoic acid in serum from unfasted control animals
(t4=2.5). Paired Student‟s t-test n=5 SD.

Interestingly, although Linoleic acid did not show a significant increase in
respiration or a decrease in ROS production, it was significantly increased in serum after
24hrs of fasting (Figures 3.6). Oleic, Eicosapentaenoic, and Arachidonic acids were also
increased after a 24hr fast, which further suggests that they play role in fasting induced
UCP mediated neuroprotection (Figures 3.7-3.8). Although Docosahexaenoic acid
showed an increased level after 24hrs of fasting, this difference was not significant
(Figures 3.10). However, the p value was 0.0974, which could indicate a trend in the
upregulation of this FFA.

Brain and CSF
In order to determine the levels of FFAs in brain we used both a control and
fasted group. However, because the harvesting of these samples inherently results in the
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mortality of the animal we could only collect endpoint samples at 24 hours in each group.
Therefore we have expressed our values as % Control, which was the unfasted group of
animals, and have used an unpaired t-test to compare the changes of FFAs between
groups.
As in our serum samples, Linoleic acid was increased in hippocampal and cortical
tissue from animals fasted for 24hrs (Figure 3.11). In contrast to fasted serum samples,
Oleic acid was not significantly increased in hippocampal tissue, but was increased in
cortical tissue (Figure 3.12).Arachidonic acid also showed a significant increase in
hippocampal tissue from fasted animals (Figure 3.13). EPA and DHA also remained
unchanged in either brain region from fasted animals (Figures 3.14-3.15). CSF
concentrations were unchanged for all of the FFAs measured in our study, which may
indicate the uptake and utilization of these FFAs (Figures 3.11-3.15).

88

A.

Cortex

C.

B.

Hippocampus

CSF

Figure 3.11 The effect of fasting on Linoleic acid levels in brain and CSF.
Animals fasted for 24 hours showed significantly increased levels of Linoleic acid in
Cortical (t8=2.6) and Hippocampal (t7=3.3) tissue. However, these animals did not show
significantly increased levels in CSF (t6=0.21). Unpaired student‟s t-test, * p< 0.05, ***
p<0.001 SD.
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Figure 3.12 The effect of fasting on Oleic acid levels in brain and CSF.
Animals fasted for 24 hours showed significantly increased levels of Oleic acid in
Cortical (A) tissue (t8=2.5). However, these animals did not show significantly increased
levels in Hippocampal (t7=1.8) tissue (B) or CSF (C) (t6=0.24). Unpaired student‟s t-test,
* p< 0.05, SD.
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Figure 3.13 The effect of fasting on Arachidonic acid levels in brain and CSF.
Animals fasted for 24 hours showed significantly increased levels of Arachidonic acid in
Hippocampal tissue (B) (t6=4.0). However, these animals did not show significantly
increased levels in Cortical tissue (A) (t8=0.95) or CSF (C) (t6=0.29). Unpaired student‟s
t-test, ** p< 0.01, n=5 SD.
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Figure 3.14 The effect of fasting on Eicosapentaenoic acid levels in brain and CSF.
Animals fasted for 24 hours did not show significantly increased levels of
Eicosapentaenoic acid in Cortical tissue (A) (t8=1.7), Hippocampal tissue (B) (t8=0.42),
or CSF (C) (t6=0.86). Unpaired student‟s t-test, n=5 SD.
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Figure 3.15 The effect of fasting on Docosahexaenoic acid levels in brain and CSF.
Animals fasted for 24 hours did not show significantly increased levels of
Docosahexaenoic acid in Cortical tissue (A) (t8=0.59), Hippocampal tissue (B) (t8=0.85),
or CSF (C) (t6=1.8). Unpaired student‟s t-test, n=5 SD.
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Discussion
Classically, Uncoupling proteins have been characterized as an intregral part of a
complex endogenously controlled system designed to protect mitochondrial function
during times of increased oxidative stress (Garlid et al. 2001; Echtay et al. 2003;
Mattiasson et al. 2003). This mechanism is an important component in every body
system, and is particularly vital in the brain due to the lack of regeneration and the
oxidative sensitivity of neural tissue. In times of neuronal insult and subsequent
secondary injury cascades, the uncoupling mechanism operates to preserve mitochondrial
function so that cellular repair mechanisms can enable the cell to recover and regain
control of its functions (Nicholls 2002; Sullivan et al. 2003; Brookes et al. 2004; Lifshitz
et al. 2004; Sullivan et al. 2004). The inhibition of these repair processes or the
inundation of these mechanisms with overwhelming damage results in cognitive
dysfunction due to lost or damaged tissue, which can decrease the ability of TBI patients
to effectively re-enter and function in society.
In our studies, we have shown robust upregulation of UCP2, the most
ubiquitously expressed UCP in the body, in neuronal mitochondria in response to fasting
(Fig.3.2). These results indicate that we can upregulate UCP2, and possibly the brain
specific uncoupling proteins UCP 4/5, using a fasting paradigm in order to study its
function in response to FFA administration. Also, it should be noted that neuronal
mitochondria are not equipped to use FFA oxidation for the production of energy
(McKee et al. 2003), which could make this system uniquely suited for induction within
the neuroprotective mechanism of fasting after injury.
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Valproic acid has become an efficacious clinical treatment for both partial and
generalized seizures; with its primary mechanism of action being the blockage of Ca2+
channel in order to prevent the release of aberrant amounts of neurotransmitter (Pellock
et al. 2001). However, there have been other suggested mechanisms for valproic acid,
such as increasing glutathione expression and activity via the upregulation of the
glutamate-cysteine ligase (GCL), which is the rate limiting enzyme in Glutathione
synthesis (Cui et al. 2007). As such, we investigated the possibility that valproic acid
could act as an endogenous uncoupler of mitochondria as an additional alternative
mechanism of action. Although valproic acid has been shown to be a neuroprotective
agent, our results indicate that it is not involved in the UCP mediated anti-ROS
mechanism. The failure of valproic acid to modulate ROS production may be due to the
small time window in which it has been incubated in these studies; which may further
implicate it in the modulation of the glutathione system rather than the UCP antioxidative mechanism.
Oleic acid, which constitutes ~55-80% of olive oil, has been previously shown to
lower biomarkers of mitochondrial stress and improve antioxidant systems and DNA
constitution when fed to rats over their life time (Quiles et al. 2006). It has been shown
to increase Glutathione Peroxidase (GPx) activity and decrease ROS production in the
presence of Antimycin A (Complex III Inhibitor), however these effects are blocked by
GPx inhibitors thereby indicating that it is working through the support of the glutathione
anti-oxidative system rather than UCP mediated ROS reduction (Duval et al. 2002).
There are, however, also reports that indicate that oleic acid can promote the initiation of
cell death pathways (Ishola et al. 2006). These contradictory findings may be the result of
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concentration differences between studies, as high concentrations of FFA can lead to the
inhibition of respiration and enhanced ROS production (Duval et al. 2002). As oleic acid
is the metabolite of Palmitic and Stearic acid pathways, it could explain why these FFAs
did not show robust induction of uncoupling or ROS reduction due to the lack of FFA
oxidation taking place within the mitochondria (Clayton et al. 1991; McKee et al. 2003).
However, in our studies Oleic acid did show a significant, although only ~10% increase
in respiration. In our ROS studies oleic acid also significantly reduced ROS production,
this could indicate that this small increase in uncoupling could have robust anti-ROS
effects. In our fasted animals, oleic acid was significantly increased in serum and cortical
tissue after 24 hrs of fasting; however we did not see an increase in hippocampal tissue,
which suggests brain region specificity of upregulation.
In our studies, Butyric acid caused an increase in respiration and a decrease in
ROS production, indicating an activation of UCPs. Interestingly butyric acid has also
been linked with a paradoxical association to cell proliferation and apoptosis, which
seems to, again, be dependent on concentration (Lupton 2004). Butyrate can also be
shunted into ketogenesis pathways, which would create an alternative fuel source for
mitochondria as well as reduce ROS production, contributing to the overall improved
mitochondrial and cellular function (Lupton 2004; Kim et al. 2007; Maalouf et al. 2007).
However, it is unlikely that it is being utilized in this pathway given the limited time
window of our studies. Our results suggest that butyric acid could be an attractive agent
to investigate in terms of a therapeutic regime designed to decrease ROS in numerous
neurological disorders.

96

Myristic acid was found to be able to increase respiration and reduce ROS
production via UCP mediated uncoupling. This FFA is a highly hydrophobic saturated
fatty acid that easily becomes embedded within membranes, which makes it an ideal
membrane localization agent for many enzymes (O'Neil 2001). This would be beneficial
to the activation of UCPs due to their membrane bound functionality. Also, if the
activation site of UCPs is within the membrane, this type of FFA would be well suited for
targeting to that location. However, the exact mechanism of UCP function has been
considered controversial; either being an activated pore structure or a platform for the
protonation and “flip-flop” of FFA across the inner membrane (Garlid et al. 2000; Echtay
et al. 2001; Garlid et al. 2001; Echtay et al. 2002). In either case, Myristic acid would be
well suited for the activation of UCPs and translocation of protons due to its long chain
length and localization characteristics.
Although the increase in respiration from state IV due to palmitic acid was
significantly different from its BSA addition rate, this value was not increased above
100% of state IV nor was it able to significantly decrease ROS production. This fatty
acid, which has been shown to be somewhat detrimental in terms of cholesterol levels,
has also been shown to shut down the mitochondrial respiration and induce the formation
of the mitochondrial permeability transition pore (MPTP) when used at high
concentrations (Nestel et al. 1994; Penzo et al. 2002). However, at lower concentrations,
similar to those we have used in our studies, it has not been shown to have a deleterious
effect on mitochondria in terms of ΔΨ and cytotoxicity (Penzo et al. 2002). Also,
previous work from our lab has shown that palmitic acid is an activator of upregulated
uncoupling proteins in isolated mitochondria from animals on the ketogenic diet
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(Sullivan et al. 2004). However these studies used a higher concentration and animals
were maintained on the ketogenic diet for 10-12 days, which could have an alternate
effect on the upregulation of UCPs in terms of expression level and isoform upregulation.
It was not shown to increase UCP expression in vitro through PPAR (Armstrong et al.
2001), which would limit its involvement to the activation of UCPs. Overall, this fatty
acid could have beneficial or detrimental effects in regards to mitochondrial and cellular
function depending on the amount and duration of exposure, however, in our studies it
did not prove to increase respiration or decrease ROS production.
When we investigated the upregulation of certain FFAs during fasting, we found
that the activation of UCP mediated uncoupling and ROS reduction by Oleic acid, EPA,
and AA corresponded with increased serum levels after a 24hr fast. However, the
upregulation of Linoleic acid in serum and brain tissue did not correspond with its ability
to activate UCP mediated uncoupling and reduce ROS. This equivocal outcome of our
studies could be explained by the fact that Linoleic acid can be converted into
Arachidonic acid simply by adding a two carbon unit (McKee et al. 2003). Also, Linoleic
has been shown to activate multiple isoforms of peroxisome proliferator activating
receptors (PPAR), which is the primary mechanism of UCP upregulation and expression
(Moya-Camarena et al. 1999; Moya-Camarena et al. 1999). Therefore, as Linoleic acid is
increased in serum and brain tissue after fasting, but lacks direct effects on UCP
activation, it may be utilized as a precursor of AA and a means by which the neural cells
can upregulate the entire UCP system. Collectively, these data indicate that it is playing a
role in the UCP mediated mechanism of fasting induced neuroprotection, and that certain
FFAs could have play a therapeutic role in the treatment of TBI.
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It has previously been shown that TBI increases Arachidonic acid levels in tissue
taken from both the injury site and the surrounding penumbra (Scheff et al. 2004). The
source of this FFA is believed to be the catalysis of membrane phospholipids by
phospholipases. AA has been implicated as a detrimental factor in a number of tissues,
where it has been shown to increase mitochondrial ROS in various mitochondrial
bioenergetic manipulations (Cocco et al. 1999; Cao et al. 2004). This FFA, which is an
essential fatty acid that is highly incorporated into membranes, also functions as the key
substrate in the prostaglandin mediated second messaging (Armstrong et al. 2001;
Halliwell et al. 2007). As we have shown in our studies, UCP2 expression is not
significantly increased by injury alone, which would indicate that TBI induced FFAs are
not involved in a uncoupling mediated protective mechanism. However, AA, as well as
its downstream products EPA and DHA, has exhibited a role in the UCP mediated
reduction of ROS suggesting a protective role within an uncoupling mechanism.
Manipulations in previous studies showing detrimental effects of AA did not
induce the upregulation of UCPs, which would leave the mitochondria unable to utilize
FFAs for ROS reduction, and as such could account for the conflicting results. Indeed,
the fasting mediated upregulation of AA and EPA, as well as the AA precursor Linoleic
acid, in serum and brain indicates that they may be involved within the previously
described neuroprotective mechanism of fasting (Davis et al. 2008). Along with Oleic
acid, which is also increased in serum and brain tissue after fasting, these FFAs have
demonstrated the capability to upregulate hepatic UCP2 through a prostaglandin
mediated PPARα induction pathway (Armstrong et al. 2001). This effect was not
maximized until 36 hours after administration (Armstrong et al. 2001), which suggests
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that prolonged upregulation of these FFAs, through the mechanism of fasting, is required
to properly upregulate and activates UCPs.
ROS is generated as a result of the blockage of electron flow through the ETC,
which causes the extension of the half-life of Q cycle intermediates, increasing the
possibility of superoxide formation and oxidative stress. FFAs can be endogenously
synthesized within the body via the breakdown of triglycerides, or they can be produced
after injury due to activated lipases (Chan et al. 1982). The transient uncoupling of the
ETC by UCPs has been suggested to be both ROS dependent and FFA activated; and that
this uncoupling is a self regulated process due to the requirement of certain levels of both
of these factors (Garlid et al. 1998; Garlid et al. 2001; Echtay et al. 2002; Echtay et al.
2003). Meaning, once the ROS levels decrease past a specific threshold, UCPs cease the
translocation of protons into the matrix. This could explain why the expression of these
proteins does not automatically lead to a total depolarization of the mitochondrial inner
membrane, which would in turn initiate cell death pathways.
The production of 4-hydroxy-2-nonenal, a product of TBI induced lipid
peroxidation, may be a mechanism designed to decrease oxidative damage through the
activation of UCPs (Echtay et al. 2003; Echtay et al. 2007). However, this injurymediated mechanism may not be sufficient to upregulate proper levels of UCPs or to
adequately sustain their activation, and as such does not result in neuroprotection. Fasting
could provide a sufficient mean of upregulation and activation of these proteins, which
could be due to its ability to increase levels of FFAs involved in multiple pathways of
regulation. Although we did not measure all of the FFAs that showed UCP activation,
fasting could result in increased levels of these FFAs and as such could augment the
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activation of UCPs. This system seems to be an innate defense mechanism, and due to the
endogenous regulation, it presents an attractive site of intervention to alleviate
mitochondrial damage and dysfunction. Although it would be ideal to identify all of the
FFAs that are increased as a result of fasting, the identification of the FFAs within our
studies has yielded interesting results, which has implicated PPAR and UCP in the
underlying mechanism of fasting induced neuroprotection.

Conclusions
In light of our previous data showing that fasting is neuroprotective after TBI, the
identification of the FFAs that are upregulated during fasting, increase UCP mediated
mitochondrial respiration, and reduce ROS production is an important step in the further
elucidation of this endogenous neuroprotective mechanism. This information could prove
important in the development of potential therapies for various neurological insults and
disorders, as well as add to the understanding of the mechanism underlying current
therapeutic treatments such as the ketogenic diet. To this end, due to the endogenous
regulatory nature of this system, therapies could potentially be designed to supplement
specific FFAs or to induce their synthesis within the body after the onset of damage.

Copyright © Laurie M. Davis 2008
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Chapter 4
The Effect of UCP2 Gene Dosing After Traumatic Brain Injury in a Mouse Model
Introduction

The basis of mitochondrial function is the utilization of the translocation of
protons from the intermembrane space to the matrix coupled to the phosphorylation of
ADP. This process relies on the function of the electron transport chain (ETC), which is a
series of protein complexes responsible for creating a charge potential across the inner
membrane. It is critical that this membrane potential (ΔΨ) be maintained within a specific
range in order to ensure proper mitochondrial function (Nicholls et al. 2002). A large
increase in ΔΨ will cause a backup of electrons within the ETC, causing an increase in
reactive oxygen species (ROS) production, which can damage mitochondrial proteins,
lipids, and DNA (Cadenas et al. 2000). Conversely, a substantial decrease in ΔΨ will
cause the consumption of ATP through the reversal of the ATPsynthase in an attempt to
recover ΔΨ, resulting in decreased ATP levels within the cell (Nicholls et al. 2000). The
maintenance of adequate ATP levels is critical to the function of cellular ion translocators
to maintain ionic balance, which is vital to neuronal function. Clearly, any major
deviation in ΔΨ can cause lasting and devastating effects on mitochondrial function and
may lead to the initiation of cell death pathways, and ultimately cognitive dysfunction.

Fortunately, endogenously regulated mitochondrial uncoupling, mediated by
members of the uncoupling protein (UCP) family, could alleviate increased ΔΨ resulting
from mitochondrial stress. The function of these proteins is to dissociate ATP production
from the ETC in the mitochondria of muscle and fat tissues (Nicholls et al. 2000);
subsequently leading to heat generation. UCPs translocate protons across the inner
102

mitochondrial membrane into the matrix, bypassing the ATPsynthase and dissipating
mitochondrial ΔΨ (Richard et al. 2001; Nicholls David et al. 2002). Their expression is
believed to be upregulated by fasting mechanisms, and their function is activated by free
fatty acids produced via beta oxidation (Dulloo et al. 2001; Sullivan et al. 2004).

Although UCP1 was the first isoform to be identified and is the most highly
studied, it wasn‟t until the late 1990‟s that researchers found additional UCP1 homologs.
Five mitochondrial UCPs have been identified in the human genome, and although all of
the UCPs have a sequence homology, their physiological role(s) are unclear in regard to
the CNS (Dulloo et al. 2001; Nicholls David et al. 2002). Among these characterized
UCPs, UCP2, UCP4 and UCP5/BMCP1 have recently been shown to be significantly
expressed in the CNS (Horvath et al. 1999; Arsenijevic et al. 2000; Diano et al. 2000;
Kim-Han et al. 2001). UCP2 was also found to be localized ubiquitously throughout the
body, and a substantial amount was found to be localized in various parts of the brain;
including the hypothalamus (suprachiasmatic, paraventricular, dorsomedial, ventromedial
nucleus and arcuate nuclei), brainstem, and limbic system; which suggests that UCP2
plays a role in neuroedocrine, behavioral, and autonomic functions (Horvath et al. 1999;
Richard et al. 2001). This expression has been found to be mainly neuronal; although the
identity of the type of neuron that is participating has been somewhat unclear. It has
recently been accepted that neurons involved in the upregulation of UCP2 possess an
atypical β3 adrenergic receptor that releases noradrenalin in response to SNS signaling,
which activates BAT thermogenesis and liberation of fatty acids (Dulloo et al. 2001;
Nicholls 2001). Highlighting this pathway were studies showing animals treated with a β3
agonist experiencing weight loss associated with UCP expression (Dulloo et al. 2001).
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UCP2 knockout animals have an increased ability to secrete insulin, which may suggest a
role for UCP2 in energy metabolism by functioning as a negative regulator of insulin
secretion (Richard et al. 2001; Erlanson-Albertsson 2002).

Free radical production is a byproduct of ATP generation in mitochondria via the
electron transport chain.

Electrons escape from the chain and reduce O2 to (O2-.).

Normally cells convert O2-. to H2O2 utilizing both manganese superoxide dismutase,
which is localized to the mitochondria, and copper-zinc superoxide dismutase found in
the cytosol. H2O2 is rapidly converted to H2O via catalase and gluthione peroxidase, but
has the potential to be converted to the highly reactive hydroxyl radical (OH) via the
Fenton reaction, underlying ROS neurotoxicity. OH rapidly attacks unsaturated fatty
acids in membranes causing lipid peroxidation and the production of 4-hydroxynonenal
(HNE) that conjugates to membrane proteins, impairing their function (Keller et al. 1997;
Keller et al. 1997; Mark et al. 1997; Sullivan et al. 1998). Such oxidative injury results in
significant alterations in cellular function. In particular, ROS induced lipid peroxidation
and protein oxidation products may be particularly important in neurodegeneration (for
review see (Mattson 1998)) and TBI (Braughler et al. 1985; Braughler et al. 1989;
Braughler et al. 1992; Sullivan et al. 1998).
Mitochondrial ROS production is intimately linked to  such that
hyperpolarization (high ) increases and promotes ROS production (Skulachev 1996;
Skulachev 1998; Votyakova et al. 2001). The underlying mechanism of this relationship
is the alteration of the redox potential of ETC carriers (reduced) and prolonged
semiquinone anion half-life time (high  prevents bh oxidation of cytochrome b1 in the
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Q cycle). In other words, at a high , protons can no longer be pumped out of the
matrix (against the electrochemical proton gradient) causing electron transport to
slow/stall. This results in intermediates staying reduced longer and increasing the chance
that the electrons will escape from these intermediates to increase ROS production. Since
the magnitude of ROS production is largely dependent on--and correlates with--, even
a modest reduction in  via increased proton conductance across the mitochondrial
inner membrane (uncoupling) can reduce ROS formation (Skulachev 1996; Kim-Han et
al. 2001; Votyakova et al. 2001). Endogenous mitochondrial uncoupling mediated by
members of the UCP family could participate in the reduction of ROS production via this
increased proton conductance. UCPs are activated by FFAs and superoxide, and inhibited
by purine nucleotides, indicating that they are sensitive to both ROS and ATP levels
(Echtay et al. 2002) (also see (Harper et al. 2001; Argiles et al. 2002; Zackova et al.
2002) for review).

Several hypotheses have been put forth concerning possible physiological roles of
the UCPs including energy partitioning, energy balance and control of metabolism which
may be pivotal in obesity and diabetes (for review see (Argiles et al. 2002; Jezek 2002)).
Skulachev was the first to hypothesis that mild uncoupling could be beneficial as it
causes a decrease in ROS production (Skulachev 1996). Several studies have now
demonstrated roles for UCPs in modulating ROS production. UCP2 (Arsenijevic et al.
2000) and UCP3 (Vidal-Puig et al. 2000) knockout mice exhibit increased ROS in
macrophages and muscle, respectively. Leptin-deficient mice have decreased levels of
UCP2 and also show increased ROS production in macrophages (Lee et al. 1999). In
vitro overexpression of UCP2 (Li et al. 2001) or UCP5/BMCP1 (Kim-Han et al. 2001)
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decrease cell death following H2O2 exposure and ROS production respectively. Finally
our lab has recently reported a neuroprotective role for UCP2 in excitotoxic cell death in
vivo (Sullivan et al. 2003). These studies demonstrated that reducing UCP2 expression
and activity, increases kainic acid induced mitochondrial ROS production and neuronal
cell loss in p12 rats pups, which are classically resistant to excitotoxic insult (Sullivan et
al. 2003). Together these studies have implicated UCPs, specifically UCP2, 4, and 5, to
play a role in protecting the mitochondria from both increased calcium uptake and
increased oxidative stress (Sullivan et al. 2003).

It is important to note that UCPs do not cause the complete uncoupling of
mitochondrial function, which would result in total energy failure and the initiation of
cell death pathways. Instead, they cause a mild transient reduction of ΔΨ within a
specific range, which allows for a dramatic decrease in ROS production. Also, because
UCPs are activated by both ROS and FFAs, which includes lipid peroxidation product 4hydroxy-2-nonenal (HNE) (Echtay et al. 2003; Echtay et al. 2007), the decrease in ROS
levels would decrease activation of UCPs. This endogenous regulation of their activation
makes them an attractive modulatory target for treatment after TBI. Therefore, in our
current studies we have investigated the role of UCP2 by means of gene dosing in an
attempt to elucidate its role in neuroprotection after TBI.
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Materials and Methods
Animals
These experiments were conducted using 6-8 week old transgenic and knockout
male mice, which have been extensively characterized (Horvath et al. 2003; Andrews et
al. 2005) were housed 3 per cage in a facility which maintained a 12-hour light/12-hour
dark cycle. All experimental animal procedures were approved by the Yale University
Animal Care and Use Committee. All animals were fed a balanced diet ad libitum before
and after injury. 6 animals were used per each of the 6 strains for tissue sparing
assessments for a total of 36 animals for these studies. A subset of animals was used to
assess oxidative damage markers within the injured tissue.

Surgical Procedures and Experimental Paradigms
These methods were performed as described previously in chapter 2. The main
difference in these studies is that a pneumatically controlled impactor with a 3mm tip
traveling at 3.5m/s compressed the exposed cortex 0.5mm in depth to deliver a moderate
injury. Premade dental acrylic caps were secured with methyl-methacrylate over the
exposed craniotomy and allowed to dry before closing the skin with surgical staples.
Animals were allowed to recover in home cages and regained consciousness and mobility
within 15-20 minutes.

Tissue Preparation and Tissue Sparing Assessment
These methods were performed as described previously in chapter 2.
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Oxidative Damage Markers
A separate set of sections from the injured animals were used to determine the
amount of oxidative damage within each group. Only homozygous (transgenic and
knockout) and wild type (transgenic and knockout) groups were used for these studies.
Tissue sections were rinsed with 0.2M Phosphate-buffered Saline (PBS), after which they
were reduced by exposing them to a solution containing 0.1M NaBH4 and 0.1M MOPS at
pH 8.0. After rinsing sections in PBS, they were incubated in 0.3% H2O2 at room
temperature (25°C). Tissue was then incubated in blocking buffer (0.2M PBS, 5.0% goat
serum, 0.25% Triton X-100, and 1.0% dry milk) and subsequently incubated in blocking
buffer containing polyclonal rabbit anti-HNE antibody (1:5000) and monoclonal mouse
anti-3NT (1:1000) overnight (Calbiochem® Darmstadt, Germany). Sections were then
incubated with fluorescent (800nM) secondary goat anti-rabbit antibody and (700nm)
goat anti-mouse antibody (Rockland Immunochemicals Inc, Gilbertsville, PA). Sections
were allowed to dry and imaged on a LiCore imager at 800nM.

Statistical Analysis
For all statistical comparisons, significance was set at p < 0.05. Data were
evaluated using analysis of variance (ANOVA) or an unpaired t-test as appropriate.
When warranted by the ANOVA, post hoc comparisons employed the Student-NeumanKeuls analysis. Importantly, as the transgenic and knockout mice were bred on different
background strains, we did not compare these groups within our statistical analysis.
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Results
After a 0.5 mm CCI injury, heterozygous and homozygous UCP2 over expressing
mice showed significantly increased neuroprotection in terms of tissue sparing compared
to wild type littermates (Figure 4.1). However, homozygous and heterozygous UCP2
knockout animals did not show a significant difference in tissue sparing compared with
their wildtype injured littermates (Figure 4.2). Although all of the groups were injured

Figure 4.1: UCP2 overexpression increases neuroprotection after TBI.
Homozygous and heterozygous UCP2 transgenic overexpressing mice showed
significantly increased tissue sparing after a 0.5mm CCI injury compared to their wild
type littermates. ANOVA F2,17=4.8, R2=0.39, *p<0.05 SNK n=6/group SD.
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and processed within the same experiment, the transgenic and knockout mice were bred
on different background strains, and therefore were not statistically compared to each
other.
In order to correlate increased tissue sparing with decreased cellular damage we
assessed tissue for modulations in the levels of HNE and 3NT, which is a marker for lipid
peroxidation and protein oxidation, respectively. This tissue assessment was performed
with the same tissue we had used for the previously shown tissue sparing assessments.
Unfortunately we failed to see UCP2 mediated modulation of HNE or 3NT levels in any

Figure 4.2: UCP2 knockout does not decrease neuroprotection after TBI.
Both Homozygous and heterozygous UCP2 knockout mice failed to show significantly
different amounts of tissue sparing after a 0.5mm CCI injury compared to their wild type
littermates. ANOVA F2, 17=1.1, R2=0.12, n=6/group SD.
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of the groups (Figure 4.3). Homozygous overexpressing mice exhibited similar levels of
HNE and 3NT at 7 days post injury compared to their wild type littermates. Although
homozygous knockout animals would be expected to show increased levels of HNE and
A.

B.

C.

D.

Figure 4.3: Effect of UCP2 expression modulation on HNE production after
traumatic brain injury.
A) Mice overexpressing human UCP2 did not show decreased levels of HNE expression
at 7 days post injury. p>0.05 t5=0.38. B) Mice lacking UCP2 did not show a significant
increase in HNE expression at 7 days post injury. p>0.05 t6=0.89. C) Mice
overexpressing human UCP2 did not show decreased levels of 3NT expression at 7 days
post injury. p>0.05 t5=0.63. D) Mice lacking UCP2 did not show a significant increase in
3NT expression at 7 days post injury. p>0.05 t 6=0.23. Unpaired students t-test, SD,
n=4(KO+/+), 4(wt +/-), 3(TG+/+), and 4 (wt +/-).
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3NT, they instead exhibited a similar level of each marker compared with their wild type
littermates. This could indicate that UCP2 does not play a role in lipid peroxidation
modulation; however, it could also indicate that by 7 days post injury HNE and 3NT
levels have been reduced by intracellular systems.

Discussion
Our current results indicate that UCP2 can play a role in neuroprotection after
TBI within a mouse model of CCI. Interestingly, we did see a significant increase in
tissue sparing in our transgenic overexpressing mice after TBI, which indicates that
increased UCP2 levels beneficially affect neuroprotection. However, we did not see a
decrease in tissue sparing after TBI in mice that lacked UCP2. This may indicate a
compensatory mechanism of other UCP isoforms (4/5) within these knockout animals.
This compensation may also be present in our transgenic mice, and as such may prevent
us from adequately assessing the effect of UCP2 modulation within neuroprotection after
TBI. Interestingly, UCP2 overexpressing mice are less susceptible to stroke induced
damage and cell death, which they propose is due to UCP2 mediated inhibition of MPTP
and caspase dependent apoptosis (Mattiasson et al. 2003). Within this study they also
found that transgenic UCP2 mice had decreased TBI induced lesion volume and
improved neurological outcome compared to wild type (Mattiasson et al. 2003), however
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our studies are a more rigorous assessment of the genetic influences of UCP2 expression
on TBI induced tissue damage due to our gene dosing paradigm. Both studies are
important to the understanding of the neuroprotective role of UCP2.
Due to the influence of UCP2 on the metabolic system, it may affect how animals
consume food after injury. However, where it has been shown that mice overexpressing
UCP2 actually consume more food (Horvath et al. 2003), the opposite has not been
shown for UCP2 knockout mice. Therefore, we cannot attribute the induction of
neuroprotection to a fasting related mechanism in either the knockout or transgenic
animals. Also, because there is not a large drop in the availability of glycolytic substrate
due to decreased food intake, both knockout and transgenic animals would lack fasting
induced upregulation of FFA forcing their UCPs to rely on the endogenous production of
lipid peroxidation byproducts (HNE) for activation (Echtay et al. 2007). Interestingly,
there have been reports showing an increase in FFAs after TBI (Scheff et al. 2004),
however this FFA profile may not be sufficient for UCP activation. Therefore, future
studies with our UCP2 knockout and transgenic animal model utilizing fasting to
upregulate these endogenous activators would give us a better understanding of the role
of UCP2 within the mechanism of fasting induced neuroprotection. Also important to the
elucidation of the neuroprotective role of UCP2 would be the development of knockout
and overexpressing mice for the remaining UCP isoforms.
Although the two strains were not directly compared statistically, there seems to
be some difference in their response to our injury model. Unfortunately, the responses of
these mouse strains have not been extensively characterized in a CCI model of injury.
Therefore, there could be strain effects on the level of cortical damage and what level of
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injury constitutes a moderate injury. However, it is important to note that neither strain is
impervious to kainic acid administration, which indicates these strains are indeed
susceptible to secondary injury mechanisms (McKhann et al. 2003). Further studies
comparing tissue sparing with multiple injury levels would need to be conducted for a
full characterization these strains within our injury model. We feel that this strain
difference would not affect our findings as these strains were not directly compared,
however the terminology of “moderate injury” may not hold true for both strains.

Conclusion
These studies are the first to describe the effect of UCP2 expression modulation
on tissue sparing after TBI. They indicate that the elevation of UCP2 expression after
TBI could have profound effects on the sparing of tissue. Although more studies would
be needed to correlate this tissue sparing with functional recovery, our results have
implicated UCP2 as a potential therapeutic target for the attenuation of tissue loss after
injury.

Copyright © Laurie M. Davis 2008
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Chapter 5
Summary and Conclusions
The elucidation of the underlying mechanism of fasting-induced neuroprotection
is an important step in the development of post-injury treatment therapies for acute TBI.
This mechanism has the advantage of post-injury initiation, as well as the fact that it does
not require the use of pharmaceutical agents. It utilizes endogenously upregulated factors
to mediate neuroprotection, and as such may not carry the same potential side effects of
many pharmaceutical interventions. To this end, the work done in these studies has
attempted to discover how something as simple as fasting could have such substantial
effects on neuroprotection, and may influence the future of clinical management of TBI.
Our studies have potential implications not only for the development of novel
therapies for the treatment of TBI, but also for the revision of the current treatment
protocols currently utilized to treat TBI patients. We have shown that insulin
administration after injury can have highly detrimental effects on tissue sparing, and can
increase mortality after moderate TBI. This is in agreement with studies showing
detrimental outcome with high glucose administration (Robertson et al. 1991; Yager et al.
1992; Cherian et al. 1998). However, clinicians are in a difficult situation due to the need
to provide metabolic substrates and at the same time minimize detrimental effects of
hyperglycemia. Therefore, they are required to use insulin administration to regulate the
levels of blood glucose in TBI patients. The problem with initiating insulin mediated
hypoglycemia or normoglycemia is that it effectively shuts down ketogenesis, which we
have shown in our current studies to be neuroprotective. Interestingly, although TBI
results in a metabolic storm in which ATP levels decrease and glucose is highly
consumed, the supplementation of metabolism with glycolytic substrates does not
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translate to the preservation of tissue or beneficial outcome. In fact, it has been
demonstrated that the utilization of glucose by the cell is shifted from ATP production
into the pentose phosphate pathway (PPP), which is responsible for the production of
NADPH and the preservation of the glutathione system (Bartnik et al. 2007; Dusick et al.
2007). This shift can be explained by the increased demand on the glutathione system as
a result of the production of oxidative damage molecules after the initiation of the
secondary injury cascade (Bartnik et al. 2007). Clearly, there is a great need for
glycolysis to alter its enzymatic pathway in order to maintain mitochondrial antioxidative mechanisms. However, it also seems imperative that mitochondrial energy
substrates must be provided in order to maintain mitochondrial function, as well as
protect cellular energy production and prevent cell death and cognitive dysfunction.
Therefore, a treatment protocol must be developed that can maintain glycolytic
substrates, in order to maintain anti-oxidative mechanisms, as well as supplement
metabolic energy production.
Oxidative damage has been shown to have significant effects on cellular damage
and endogenous repair mechanisms at early time points after traumatic brain injury in
both cortical and hippocampal regions (Ansari et al. 2008; Ansari et al. 2008). Reports of
increased lactate levels after TBI could be linked to oxidative damage of the pyruvate
dehydrogenase complex (PDHC), which is responsible for the conversion of Pyruvate
into Acetyl CoA, the initial compound of the Krebs cycle. The PDHC is highly sensitive
to oxidative damage resulting from neurological pathology, and as such can cause
increased lactate formation and the depletion of energy within the cell (Martin et al.
2005). Therapies designed to overcome the PDHC block, using acyl-L-carnitine, indicate
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that bypassing the enzymatic complex through Krebs cycle intermediate supplementation
can stimulate aerobic metabolism by reducing lactate production and tissue acidosis
arising from glycolitic metabolism (Martin et al. 2005). The shift to the PPP, coupled
with the decreased ability of the cell to produce Krebs cycle intermediates, could lead to
energy failure after injury. Fortunately, ketones are able to bypass the glycolytic block
induced by oxidative damage mediated PDHC inactivation, supplying the Krebs cycle
with intermediates for ATP production via oxidative phosphorylation (Martin et al.
2005). Our results indicate that ketones significantly increased tissue sparing after
moderate TBI, as well as in vitro improvements in mitochondrial function in
excitotoxicity models. This may indicate a central role in the neuroprotective mechanism
of fasting for ketone metabolism.
Indeed, the utilization of ketones in the absence of fasting would allow the cell to
complete its glycolytic shift to the PPP, while providing the necessary substrates for the
production of energy (Figure 5.1). Interestingly, there is also evidence indicating that the
utilization of ketones, and subsequent production of succinate, can stabilize HIF-1α and
thereby upregulate HIF-1 genes (Puchowicz et al. 2008). This is also supported by studies
showing mutations in succinate dehydrogenase, resulting in increased succinate levels,
also cause HIF-1 mediated gene expression (Gottlieb et al. 2005; Selak et al. 2005). As
these genes are highly involved in glycolytic enzyme and glucose transporter
upregulation (Schofield et al. 2004; Sharp et al. 2004; Berra et al. 2006), this pathway
could further support the shift to the PPP. Indeed there is a significant decrease in a key
PPP enzyme glucose-6-phosphate dehydrogenase (G6PD), which coincides with an
impairment of the endogenous glutathione system and increased oxidative markers after

117

TBI (Ansari et al. 2008). Interestingly, a putative HIF-1 binding site has been located on
the promoter region of the rat G6PD gene (Gao et al. 2004), which indicates that
succinate mediated stabilization of HIF-1 may lead to the maintenance of endogenous
antioxidant systems and decreased oxidative damage, both of which has been seen in our
current studies as well as cited literature. Indeed, ketone induced stabilization of HIF1α is
also involved in the upregulation of anti-apoptotic Bcl2 genes, indicating a role in cell
death regulation (Puchowicz et al. 2008). It is also important to note that HIF-1 induces
the upregulation of monocarboxylate transporters (ketone transporters) (Knott et al.
1999; Zhang et al. 2005), which could further supplement this system with adequate
ketogenic precursors. HIF-1 mediated upregulation of angiogenesis by VEGF (Schofield
et al. 2004) could also alleviate TBI related hypoxia within the injury site, leading to
decreased damage, and increased tissue recovery. In fact, this system seems to be both
extensively interconnected, as well as highly regulated (Figure 5.1). Although we saw
increased tissue sparing with our ketone administration, we only saw this effect at the
lower dose of βHB, which could highlight the fact that HIF-1 can also upregulate proapoptotic genes (Koivunen et al. 2007), depending on the duration and intensity of
signaling. This may be an important factor regarding treatment window and dosing
regimen when translating this treatment into an effective therapy.
Although we have provided strong evidence for ketogenesis as the underlying
mechanism of fasting after brain trauma, the amount of tissue sparing did not seem to be
as robust as our fasting studies. This could be explained by the need for more extensive

118

Figure 5.1 Revised hypothesis of how ketones and HIF-1 work together to preserve
mitochondrial function.
1) Ketones (βHB and ACA) are utilized by mitochondria to produce Krebs cycle
intermediates, which produce substrates for the ETC (NADH and FADH2). This allows
the mitochondria to produce sufficient energy, in the form of ATP, to maintain
homeostasis. 2) The conversion of ketones into acetyl-CoA also produces succinate,
which can be utilized by the Krebs cycle to produce energy. 3) Succinate has also been
shown to block HIF-1α prolyl-hydroxylases, which in turn stabilizes the levels of HIF-1α.
This allows HIF-1α to dimerize with HIF-1β and travel to the nucleus, where it is
responsible for the upregulation of proteins involved in angiogenesis, glucose uptake,
glycolysis, and ketone uptake. 4) It is through the HIF-1 mediated upregulation of MCTs
that we believed it is possible for increased ketone levels to increase their uptake into the
cell for utilization as energetic substrates. 5) Oxygen is responsible for the activation of
HIF-1α prolyl-hydroxylases, which alter HIF-1α, which allows the von Hipple-Lindau
protein to target it for proteasome mediated degradation. ROS can also inhibit HIF-1α
prolyl-hydroxylases, which may explain how HIF-1α expression is upregulated by injury.
HIF-1 upregulates glycolytic enzymes the utilization of ketones by mitochondria could be
shifting glycolytic intermediates into the (7) pentose pathways, which is responsible for
the increase of NADPH levels and in turn support of the endogenous glutathione system.
8) TBI induces oxidative damage of Glucose-6-phosphate dehydrogenase (G6PD), which
causes a failure of the glutathione system due to a lack of NADPH production by the
Pentose Phosphate Pathway (PPP). 9) HIF-1 upregulates G6PD, as well as other
glycolytic proteins, thereby alleviating the glycolytic block induced by TBI, resulting in
the restoration of the glutathione system.
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ketone dosing studies or inherent differences between studies, however because we know
that other factors are upregulated in response to fasting, we decided to investigate their
possible role within this protective mechanism.
Our studies have indicated that fasting upregulates UCP expression in cortical
mitochondria. These proteins are regulated through the peroxisome proliferator activating
receptor (PPAR) pathway. The activation of the PPAR system is primarily through free
fatty acid (FFA) ligand binding; which could explain the mechanism by which UCP
expression may be increased (though not significantly) as FFA levels have been shown to
be increased after TBI (Scheff et al. 2004), this. As UCPs are part of an endogenously
regulated anti-ROS mechanism, we sought to determine their role in fasting induced
neuroprotection. However, there has been little investigation into which of the FFAs
activate uncoupling of mitochondria. Therefore, we screened a wide range of FFAs to
determine their ability to induce uncoupling and reduce ROS production in cortical
mitochondria from fasted animals. We also wanted to correlate their function with FFA
upregulation in response to fasting in naïve animals. Interestingly, we found that FFAs
that have been shown to increase after injury, such as Arachidonic (AA) and Oleic acids
(Scheff et al. 2004), had an effect on UCP activation and ROS reduction. Oleic acid has
been implicated in the preservation of the glutathione system, and our data showing its
presence in cortical but not hippocampal tissue in response to fasting is in agreement with
the literature in which oleic acid was measured after injury (Scheff et al. 2004). As oleic
acid did not increase UCP mediated respirations in isolated mitochondria, it is most likely
functioning to reduce ROS through the glutathione system. AA, which is a known
activator of all PPAR isoforms (Jump 2002), and Linoleic acid (Moya-Camarena et al.
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1999; Moya-Camarena et al. 1999), which can be converted into AA, could be highly
involved in the PPAR mediated UCP upregulation. However, limited research has been
done to investigate their role in direct UCP activation. Our results show that AA is able to
activate UCP mediated ROS production and is significantly upregulated in the serum and
hippocampal tissue of fasted animals, which may implicate it as a protective factor after
injury. Interestingly, Eicosapenaenoic acid (EPA) and Docosahexaenoic acid (DHA),
which are produced via AA metabolism, can also activate the UCP mediated anti-ROS
mechanism in isolated cortical mitochondria. However, only EPA was significantly
increased in fasted serum samples, where DHA showed a trend toward increased levels.
Our studies represent the first measurements of specific FFAs in response to fasting, as
well as a correlation to their activation of UCPs. These data implicate these specific FFAs
in a UCP mediated protective mechanism within the neuroprotective mechanism of
fasting.
Although we had indirectly implicated UCPs as a neuroprotective factor after
TBI, we wanted to determine its role in the absence of fasting. To this end, we used
UCP2 gene dosing to assess its effect on tissue sparing after moderate TBI in a mouse
model of CCI. Our study indicates that UCP2 overexpression can be neuroprotective,
whereas UCP2 knockout shows no detrimental effect on tissue sparing. This could
indicate that other brain UCPs are compensating for the lack of UCP2 within our
knockout animals, which have been shown to have consistent expression levels among
knockout and wild type animals (Andrews et al. 2005). In addition to this compensation,
without fasting mediated upregulation of FFAs the activation of UCPs must be through
lipid peroxidation products, and as such may not be sufficient to cause a differentiation in
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neuroprotection in our knockout mice. Indeed, in a future study in which injured
transgenic and knockout mice are fasted, we may see a greater demarcation in tissue
sparing among our genetic groups.
In our UCP study using transgenic and knockout mice we saw that increased
UCP2 expression, as seen in fasted injured animals (Figure 3.2), resulted in
neuroprotection. However, as we had seen in our ketone administration study, this effect
is not as robust as that seen within our fasting study. Our modulations of UCP2 provide
evidence that it is important in neuroprotection after injury, although it is difficult to
isolate the activity of this specific protein as the underlying mechanism of fasting induced
neuroprotection. It is more probable that these two mechanisms are working in a
concerted effort to afford neuroprotection within our fasting mechanism (Figure 5.2). It
has been shown that ketones have the ability to alter the redox potential of Co-enzyme
Q10 (CoQ10) from a reduced to oxidized form, which can decrease the probability of
electron slippage and ROS formation (Maalouf et al. 2007). Interestingly, it has also been
shown that UCP mediated proton translocation not only requires ROS and FFAs, but that
oxidized CoQ10 is required for their activation as well (Echtay et al. 2000; Echtay et al.
2001; Echtay et al. 2002). In addition to this direct effect between ketones and UCP
function, FFA activation of PPARα upregulates the production of mitochondrial HMG
CoA sythetase, which is a key enzyme in ketone production (Jump 2002). As both
ketones and UCPs are upregulated by fasting and that they seem to influence each other‟s
metabolic and regulatory pathways, it is our assertion that it is the cooperation between
ketones and UCPs that comprise the underlying mechanism of fasting induced
neuroprotection. The development of treatment therapies that focus on the utilization of

122

these pathways, highlighting their interdependence, may lead to an efficacious
attenuation of neurological deficits resulting from TBI pathology.

Figure 5.2 Hypothesis of how ketones and UCPs work together as the underlying
mechanism of fasting induced neuroprotection.
1) Fasting initiates the upregulation of ketone bodies and free fatty acids (FFA). FFA can
function to induce the upregulation of UCP expression via PPAR and to activate UCP
mediated uncoupling and ROS reduction. 2) Ketones alter the redox state of Co-enzyme
Q10 (Ubiquinone), which shifts it into an oxidized state. 3) This oxidized form of Coenzyme Q10 (CoQ10ox) is required for the activation of UCPs. 4) TBI causes an increase in
ROS production, which is also required for activation of UCPs, and subsequently
mitochondrial dysfunction. 5)The backup of electrons within the ETC due to increased
membrane potential and mitochondrial function shifts Co-enzyme Q10 into a reduced state
(CoQ10red). This form of Co-enzyme Q10 has been shown to inhibit UCP function. 6) Any
UCPs upregulated as a result of TBI would be unable to confer neuroprotection due to the
lack of oxidized Co-enzyme Q10, regardless of TBI induced FFA upregulation.
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Appendix
1. 2‟-7‟-dichlorodihydrofluorescein (DCF)
2. 4 hydroxy-2-nonenol (HNE)
3. 4-(2-hydrozyethyl)piperazine-1ethanesulfonic acid potassium
salt (HEPES)
4. 8-hydroxy-2-deoxyguanosine (8ohdg)
5. Acetoacetate (ACA)
6. Adenine nucleotide translocase
(ANT)
7. Adenosine diphosphate (ADP)
8. Adenosine triphosphate (ATP)
9. Analysis of variance (ANOVA)
10. Apoptosis activation factor-1
(Apaf-1)
11. Apoptosis inducing factor (AIF)
12. Atpsynthase (complex V)
13. Beta-hydroxybutyrate (βhb)
14. Bicinchoninic acid (BCA)
15. Bovine serum albumin (BSA)
16. Brain mitochondrial carrier
protein-1 (BMCP-1)
17. Brown adipose tissue (BAT)
18. Calcium (Ca2+)
19. Calcium green 5N (cag5n)
20. Carbonyl cyanide 4(trifluoromethoxy)phenylhydrazo
ne (FCCP)
21. Carboxyl radical (CO3.-)
22. Center for disease control (CDC)
23. Co-enzyme Q10 (coq10)
24. Controlled cortical impact (CCI)
25. Cytochrome-c Oxidase (complex
IV)
26. Deoxyribonucleic acid (DNA)
27. Electron transport chain (ETC)
28. Endonuclease G (Endo G)
29. Ethylene glycol-bis (2aminoethylether)-N,N,N‟N‟tetraacetic acid (EGTA)
30. Excitatory amino acid (EAA)
31. Ferric iron (Fe3+)
32. Flavin adenine dinucleotides
(FADH2)

33. Free fatty acid (FFA)
34. Glutathione peroxidase (gpx)
35. HIF prolyl 4-hydrolase (P4H)
36. High density lipoprotein (HDL)
37. Horseradish peroxidase (HRP)
38. Hydrogen peroxide (H2O2)
39. Hydroxyl radical (.OH)
40. Hypoxia-inducible factor-1 (HIF1)
41. Inner membrane (IM)
42. Intermembrane space (IMS)
43. Intracellular calcium ([Ca2+]i)
44. Ketogenic diet (KD)
45. Low density lipoprotein (LDL)
46. Magnesium (Mg+)
47. Magnesium chloride (mgcl)
48. Manganese superoxide dismutase
(mnsod)
49. Membrane potential (ΔΨ)
50. Mitochondrial 3-hydroxy-3methylglutaryl-coa synthase
(mhs)
51. Mitochondrial permeability
transition pore (mptp)
52. Monocarboxylate transporter
(MCT)
53. Morris water maze (MWM)
54. NAD-Ubiquinone
oxidoreductase (complex I)
55. Nicotinamide adenine
dinucleotide (NADH)
56. Nitric oxide (.NO)
57. Nitrogen dioxide (.NO2)
58. N-methyl-D-aspartate (NMDA)
59. Outer membrane (OM)
60. Oxygen (O2)
61. Oxygen-dependent degradation
domain (ODD)
62. Paraformaldehyde (PFA)
63. Pentose phosphate pathway
(PPP)
64. Peroxisome proliferator
activating receptor (PPAR)
65. Peroxisome proliferator response
element (PPRE)
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66. Peroxynitrite anion (ONOO.)
67. Phosphate buffered saline (PBS)
68. Post traumatic stress disorder
(PTSD)
69. Postconcussional syndrome (PS)
70. Potassium chloride (kcl)
71. Potassium phosphate monobasic
anhydrous (KH2PO4)
72. Protons (H+)
73. Pyruvate dehydrogenase complex
(PDHC)
74. Reactive nitrogen species (RNS)
75. Reactive oxygen species (ROS)
76. Retinoid X receptor (RXR)
77. Shell shock (SS)
78. Sodium (Na+)
79. Sodium borohydride (nabh4)
80. Standard deviation of the group
mean (SD)
81. Standard error of the group mean
(SEM)
82. Succinate dehydrogenase
(complex II)
83. Superoxide (O2.-)

84. Sympathetic nervous system
(SNS)
85. Tetramethylrhodamine ethyl
ester perchlorate (TMRE)
86. Thiazolidinediones (DZT)
87. Traumatic brain injury (TBI)
88. Triacylglycerol (Tg)
89. Ubiquinone-cytochrome-coxidoreductase (complex III)
90. Uncoupling protein (UCP)
91. United states (U.S.)
92. Units (U)
93. Vascular endothelial growth
factor (VEGF)
94. Very low density lipoprotein
(VLDL)
95. Voltage-dependent anion channel
(VDAC)
96. Von Hipple Lindau tumor
suppressor protein (vhl)
97. World war I (WWI)
98. Α-amino-3-hydroxy-5-methyl-4isozazole proprionic acid
(AMPA)
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